JohnLoh00 personal page - To The Moon

JohnLoh00

No personal profile

2Follow

1Followers

0Topic

0Badge

2021-09-22

Ok

Sorry, the original content has been removed

2021-09-21

Ok

Got $1,000? Buy These Hot Growth Stocks Before They Take Off

2021-09-20

Ok

3 Stocks to Add to Your Portfolio in a Market Pull-Back

2021-09-18

Ok

Pfizer Covid-19 shot's protection against hospitalisation wanes in study

2021-09-16

Ok

Sorry, the original content has been removed

2021-09-16

Ok

Procept BioRobotics spikes 40% on its first day of trading

2021-09-16

Ok

Procept BioRobotics spikes 40% on its first day of trading

2021-09-15

Ok

Sorry, the original content has been removed

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":3580436163482352,"uuid":"3580436163482352","gmtCreate":1617342893541,"gmtModify":1617342893541,"name":"JohnLoh00","pinyin":"johnloh00","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":2,"tweetSize":21,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-1","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Debut Tiger","description":"Join the tiger community for 500 days","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.08.27","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":"80.81%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":3,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":869838777,"gmtCreate":1632271331099,"gmtModify":1676530739361,"author":{"id":"3580436163482352","authorId":"3580436163482352","name":"JohnLoh00","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/869838777","repostId":"2169637141","repostType":4,"isVote":1,"tweetType":1,"viewCount":113,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":860401147,"gmtCreate":1632193476289,"gmtModify":1676530722508,"author":{"id":"3580436163482352","authorId":"3580436163482352","name":"JohnLoh00","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/860401147","repostId":"1159687756","repostType":4,"repost":{"id":"1159687756","pubTimestamp":1632190724,"share":"https://www.laohu8.com/m/news/1159687756?lang=&edition=full","pubTime":"2021-09-21 10:18","market":"us","language":"en","title":"Got $1,000? Buy These Hot Growth Stocks Before They Take Off","url":"https://stock-news.laohu8.com/highlight/detail?id=1159687756","media":"Motley Fool","summary":"You don't need a lot of money to make a difference with the right growth stocks.","content":"<p><b>Key Points</b></p>\n<ul>\n <li>A little money can go a long way when volatility turns stocks you want to buy into even bigger bargains.</li>\n <li>Crocs is a name on this list, a surprising winner that is still sneaking up on investors with its masterful turnaround.</li>\n <li>The other two names are growing fast in a booming streaming video market.</li>\n</ul>\n<p>The market's off to a shaky start this week, but there's opportunity in the volatility. Now is a good time to size up some of the stocks on your shopping to list, asking yourself if the stories are getting better even as the stocks are going nowhere.</p>\n<p>You don't need a lot of money to take advantage of the ups and downs of Wall Street. Just $1,000 can go a long way if you are buying the right growth stocks, and right now I like&nbsp;<b>Crocs</b>&nbsp;(NASDAQ:CROX),<b>fuboTV</b>(NYSE:FUBO), and&nbsp;<b>Roku</b>(NASDAQ:ROKU). The first one is a surprising winner in 2021. The other two are surprising laggards. Even though $1,000 will buy you just a couple of shares in some of these names, let's get into why I see these as growth stocks that are about to take off.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/5eb5fb95534102c76d3a38d3bea8ad5b\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p>\n<p><b>1. Crocs</b></p>\n<p>If you haven't been following Crocs lately you may be surprised at how well the stock has been doing. The maker of hole-filled resin shoes has more than doubled in 2021, nearly quadrupling since the start of last year.</p>\n<p>Crocs has had its ups and downs over the years, but it's clearly on an upswing now. The revival started in 2017 when a new CEO came in just as the maker of unique footwear was posting its third straight year of declining sales. Revenue growth turned slightly positive in 2018 with a 6% increase, followed by back-to-back years of 13% top-line upticks. This year Crocs is running on an entirely different level.</p>\n<p>Back in February Crocs was targeting 20% to 25% revenue gains for all of 2021, a great achievement as it would be nearly doubling its growth from the prior year. In late April the guidance was bumped to 40% to 50% in top-line growth, and this summer it got boosted again. Crocs now sees a 60% to 65% increase in revenue in 2021.</p>\n<p>The pandemic made us appreciate Crocs again. We chose comfort over fashion during the shelter-in-place phase of the pandemic. Now that we're out and about again we're not giving up our Crocs. We're seeing celebrities strutting in Crocs at media events and out in the wild. Crocs are showing up in movies like this summer's&nbsp;<i>Suicide Squad</i>. The stock may have hit&nbsp;an all-time high last week, but with a lot of people still skeptical on the turnaround the bullish argument here is that the rally is just beginning.</p>\n<p><b>2. fuboTV</b></p>\n<p>When you size up the IPO class of 2020, fuboTV should be the teacher's pet. Some debutantes appear to be peaking just before their stock offerings, but the live TV streaming service is&nbsp;stepping on the gas. Let's just go over the top-line performance in fuboTV's first four quarters as a public company.</p>\n<ul>\n <li>Q3 2020: 71% revenue growth.</li>\n <li>Q4 2020: 98% revenue growth.</li>\n <li>Q1 2021: 135% revenue growth.</li>\n <li>Q2 2021: 196% revenue growth.</li>\n</ul>\n<p>A 138% increase in subscribers over the past year coupled with a 30% pop in average revenue per user is why fuboTV's revenue has nearly tripled. The near-term outlook is even more exciting. As a sports-minded streaming service -- with more than three dozen of its over 100 channels dedicated to live sporting events -- it knows its audience. It introduced free-to-play predictive games and live layered stats this summer, and it expects to roll out a sportsbook to allow viewers to place cash bets on the games they're watching before the end of the year.</p>\n<p>Despite the perpetual improvement at fuboTV the stock is roughly where it was when the year began. With sports season heating up, fuboTV's engaged audience will help it win this game.</p>\n<p><b>3. Roku</b></p>\n<p>There are worse things than standing in place, and right now Roku is trading slightly lower in 2021. It doesn't seem fair. Roku continues to be the platform of choice for folks streaming from home, with 38% of all smart TVs rolling out with Roku's operating system as the default factory-installed operating system. If you don't happen to buy a Roku-ready TV you can buy a dongle for as little as $20 to $30 that will plug into one of your TV's HDMI ports.</p>\n<p>This is a growing market, and even if viewing hours slipped this summer as we began to venture outside again the long-term trend is undeniable. We love streaming video entertainment from home. Sunday's Emmy Awards is another reminder that the best shows on TV these days are largely on premium streaming services.</p>\n<p>Despite the slight dip in sequential consumption in its latest quarter and the&nbsp;recent challenge&nbsp;of a competitor introducing its own TVs, Roku has never been better. The record 55.1 million active accounts on the platform at the end of June was a 28% increase from where it was a year ago, and like fuboTV we're seeing average revenue per user advance at a double-digit percentage clip. Roku is a worthy leader among&nbsp;streaming service stocks. The stock taking a small step back in 2021 at a time when the fundamentals continue to move forward makes this a strong candidate to take off once the dust settles.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Got $1,000? Buy These Hot Growth Stocks Before They Take Off</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGot $1,000? Buy These Hot Growth Stocks Before They Take Off\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-21 10:18 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/20/got-1000-buy-these-hot-growth-stocks-before-they-t/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Key Points\n\nA little money can go a long way when volatility turns stocks you want to buy into even bigger bargains.\nCrocs is a name on this list, a surprising winner that is still sneaking up on ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/20/got-1000-buy-these-hot-growth-stocks-before-they-t/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ROKU":"Roku Inc","FUBO":"fuboTV Inc.","CROX":"卡骆驰"},"source_url":"https://www.fool.com/investing/2021/09/20/got-1000-buy-these-hot-growth-stocks-before-they-t/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1159687756","content_text":"Key Points\n\nA little money can go a long way when volatility turns stocks you want to buy into even bigger bargains.\nCrocs is a name on this list, a surprising winner that is still sneaking up on investors with its masterful turnaround.\nThe other two names are growing fast in a booming streaming video market.\n\nThe market's off to a shaky start this week, but there's opportunity in the volatility. Now is a good time to size up some of the stocks on your shopping to list, asking yourself if the stories are getting better even as the stocks are going nowhere.\nYou don't need a lot of money to take advantage of the ups and downs of Wall Street. Just $1,000 can go a long way if you are buying the right growth stocks, and right now I like Crocs (NASDAQ:CROX),fuboTV(NYSE:FUBO), and Roku(NASDAQ:ROKU). The first one is a surprising winner in 2021. The other two are surprising laggards. Even though $1,000 will buy you just a couple of shares in some of these names, let's get into why I see these as growth stocks that are about to take off.\nIMAGE SOURCE: GETTY IMAGES.\n1. Crocs\nIf you haven't been following Crocs lately you may be surprised at how well the stock has been doing. The maker of hole-filled resin shoes has more than doubled in 2021, nearly quadrupling since the start of last year.\nCrocs has had its ups and downs over the years, but it's clearly on an upswing now. The revival started in 2017 when a new CEO came in just as the maker of unique footwear was posting its third straight year of declining sales. Revenue growth turned slightly positive in 2018 with a 6% increase, followed by back-to-back years of 13% top-line upticks. This year Crocs is running on an entirely different level.\nBack in February Crocs was targeting 20% to 25% revenue gains for all of 2021, a great achievement as it would be nearly doubling its growth from the prior year. In late April the guidance was bumped to 40% to 50% in top-line growth, and this summer it got boosted again. Crocs now sees a 60% to 65% increase in revenue in 2021.\nThe pandemic made us appreciate Crocs again. We chose comfort over fashion during the shelter-in-place phase of the pandemic. Now that we're out and about again we're not giving up our Crocs. We're seeing celebrities strutting in Crocs at media events and out in the wild. Crocs are showing up in movies like this summer's Suicide Squad. The stock may have hit an all-time high last week, but with a lot of people still skeptical on the turnaround the bullish argument here is that the rally is just beginning.\n2. fuboTV\nWhen you size up the IPO class of 2020, fuboTV should be the teacher's pet. Some debutantes appear to be peaking just before their stock offerings, but the live TV streaming service is stepping on the gas. Let's just go over the top-line performance in fuboTV's first four quarters as a public company.\n\nQ3 2020: 71% revenue growth.\nQ4 2020: 98% revenue growth.\nQ1 2021: 135% revenue growth.\nQ2 2021: 196% revenue growth.\n\nA 138% increase in subscribers over the past year coupled with a 30% pop in average revenue per user is why fuboTV's revenue has nearly tripled. The near-term outlook is even more exciting. As a sports-minded streaming service -- with more than three dozen of its over 100 channels dedicated to live sporting events -- it knows its audience. It introduced free-to-play predictive games and live layered stats this summer, and it expects to roll out a sportsbook to allow viewers to place cash bets on the games they're watching before the end of the year.\nDespite the perpetual improvement at fuboTV the stock is roughly where it was when the year began. With sports season heating up, fuboTV's engaged audience will help it win this game.\n3. Roku\nThere are worse things than standing in place, and right now Roku is trading slightly lower in 2021. It doesn't seem fair. Roku continues to be the platform of choice for folks streaming from home, with 38% of all smart TVs rolling out with Roku's operating system as the default factory-installed operating system. If you don't happen to buy a Roku-ready TV you can buy a dongle for as little as $20 to $30 that will plug into one of your TV's HDMI ports.\nThis is a growing market, and even if viewing hours slipped this summer as we began to venture outside again the long-term trend is undeniable. We love streaming video entertainment from home. Sunday's Emmy Awards is another reminder that the best shows on TV these days are largely on premium streaming services.\nDespite the slight dip in sequential consumption in its latest quarter and the recent challenge of a competitor introducing its own TVs, Roku has never been better. The record 55.1 million active accounts on the platform at the end of June was a 28% increase from where it was a year ago, and like fuboTV we're seeing average revenue per user advance at a double-digit percentage clip. Roku is a worthy leader among streaming service stocks. The stock taking a small step back in 2021 at a time when the fundamentals continue to move forward makes this a strong candidate to take off once the dust settles.","news_type":1},"isVote":1,"tweetType":1,"viewCount":176,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":860067721,"gmtCreate":1632108948463,"gmtModify":1676530702855,"author":{"id":"3580436163482352","authorId":"3580436163482352","name":"JohnLoh00","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/860067721","repostId":"2168505605","repostType":4,"repost":{"id":"2168505605","pubTimestamp":1632107672,"share":"https://www.laohu8.com/m/news/2168505605?lang=&edition=full","pubTime":"2021-09-20 11:14","market":"us","language":"en","title":"3 Stocks to Add to Your Portfolio in a Market Pull-Back","url":"https://stock-news.laohu8.com/highlight/detail?id=2168505605","media":"Motley Fool","summary":"These great stocks are just a little too expensive to be perfect investments right now.","content":"<p>Stocks are expensive right now, with the <b>S&amp;P 500</b> price-to-earnings ratio at its highest level since the dot-com bubble. That doesn't mean that investors should be selling all their stocks and waiting for the next crash. It could be a while until a correction occurs, and that sort of strategy would have caused you to miss out on the past year of market growth.</p>\n<p>Still, some shrewd investors have built more defensive portfolios and are waiting for a pull-back to scoop up great companies that happen to have aggressive valuations right now. These three stocks are great opportunities that you should consider if they get any cheaper.</p>\n<h2>Nvidia</h2>\n<p><b>Nvidia</b> (NASDAQ:NVDA) is a rockstar tech stock with outstanding growth catalysts, and it's returned more than 230% since the pandemic market bottom in March 2020.</p>\n<p class=\"t-img-caption\"><img src=\"https://media.ycharts.com/charts/e4d03dae188b51897bf508dc9b12336c.png\" tg-width=\"720\" tg-height=\"387\" width=\"100%\" height=\"auto\"><span>NVDA data by YCharts</span></p>\n<p>Nvidia is the global market leader in PC graphics processor units (GPU), with 83% market share. The company supplies microchips that are essential for gaming, high-performance video, and other applications that require more advanced visual hardware. The global video game market is expected to grow more than 12% annually over the next five years, and high-resolution video content continues to become a preferred media for consumers. Those factors alone provide catalysts for Nvidia for the foreseeable future.</p>\n<p>However, Nvidia's opportunity isn't limited to gaming and personal computing. The company's chips have important applications in data centers, the automotive and autonomous vehicle industry, artificial intelligence and automation technology, and 5G network infrastructure. Connection to those trends provides an even more enticing growth opportunity.</p>\n<p>What's the catch here? Nvidia is expensive. Its forward price-to-earnings ratio of 55 is high relative to most other semiconductor stocks, and it's substantially higher than Nvidia's own recent historical levels. Even the PEG ratio, which takes into account the company's bullish growth forecast, indicates an expensive-looking stock.</p>\n<p class=\"t-img-caption\"><img src=\"https://media.ycharts.com/charts/a51764bc0c3216578fb6c349d060cc6d.png\" tg-width=\"720\" tg-height=\"387\" width=\"100%\" height=\"auto\"><span>NVDA P/E Ratio (Forward 1y) data by YCharts</span></p>\n<p>Overall, it seems that Nvidia is a great stock to own, but there might be less expensive alternatives that can deliver better fundamentals for the price. If there's a market pull-back anytime soon, Nvidia should be <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the first stocks to consider at a lower price.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/32358a5a70714295cef5e46d939c1d3e\" tg-width=\"700\" tg-height=\"404\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Chipotle</h2>\n<p><b>Chipotle Mexican Grill</b> (NYSE:CMG) is a chain of well-known, fast-casual restaurants. The company has managed to endure a handful of scandals and an unprecedented pandemic, and it just keeps on growing. The chain's perceived value, nutrition, quality, and convenience clearly resonate with consumers. With double-digit growth forecast for this year and next, it doesn't seem like there's any reason to expect Chipotle to falter soon.</p>\n<p>Chipotle has plenty of avenues for continued growth that excite investors. It has fewer than 2,900 locations, less than half of its sales are from its digital channel, and delivery services only produce 1% of total revenue. The company produces substantial cash flow, and the only debt on its balance sheet is related to operating lease obligations, not loans. That limits financial risk and means that Chipotle could easily source capital for growth if the need arose.</p>\n<p>Once again, the issue here is really about valuation. Chipotle has often attracted aggressive valuation multiples, and its 56 forward P/E ratio seems more characteristic of a tech company than an established restaurant chain. Its enterprise-value-to-EBITDA ratio of 50 indicates that it's not a situation in which earnings per share misrepresent true profits. Chipotle is simply expensive to own. If the market gives you an opportunity to scoop up some shares at a more attractive price, it's worth consideration.</p>\n<h2><a href=\"https://laohu8.com/S/V\">Visa</a></h2>\n<p><b>Visa</b> (NYSE:V) is a household name with a brand that's nearly synonymous with credit and debit cards. People see that logo every day, and it's also featured on the front doors of countless restaurants and retailers that accept Visa cards. There's more going on under the surface here, too, and this company offers some exposure to a wider fintech revolution that's been occurring.</p>\n<p>Visa is really a payment processing network with global reach, rather than a credit card supplier. This is a rapidly evolving landscape with the likes of <b>Square</b> (NYSE:SQ), <b><a href=\"https://laohu8.com/S/PYPL\">PayPal</a></b> (NASDAQ:PYPL), countless ambitious start-ups, and various blockchain solutions springing up to bring efficiency and security to digital payments and transfers.</p>\n<p>Visa remains competitive by making acquisitions and creating partnerships with innovators that might otherwise turn into competitors. Regulators blocked its acquisition of Plaid, and Visa pivoted by purchasing the B2B cross-border payment platform Currencycloud and Tink, a European open-banking platform for consumers.</p>\n<p>Visa offers a compelling business narrative, but its value as an investment is a bit less straightforward. It's hard to consider this a value stock with a forward P/E ratio of 30.6 and a 0.6% dividend yield. Like many other stocks, Visa is near the high end of its recent range for the P/E ratio.</p>\n<p class=\"t-img-caption\"><img src=\"https://media.ycharts.com/charts/e6f09aebc95eb66f909e97fb08b12336.png\" tg-width=\"720\" tg-height=\"387\" width=\"100%\" height=\"auto\"><span>V Normalized PE Ratio (Annual) data by YCharts</span></p>\n<p>On the other hand, Visa is mature compared to other fintech stocks and doesn't have quite the same growth prospects. It's also in a tough spot as the incumbent power in an industry that's undergoing rapid evolution. If we have a market correction, Visa would suddenly look a lot better as a value investment with more upside than most. If the stock's price dips around 15%, its PEG ratio would creep toward 1.5. At that valuation, I would buy Visa hand over fist as a cash flow generator with uncommon growth potential.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks to Add to Your Portfolio in a Market Pull-Back</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks to Add to Your Portfolio in a Market Pull-Back\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-20 11:14 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/19/3-stocks-to-add-to-your-portfolio-in-a-market-pull/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Stocks are expensive right now, with the S&P 500 price-to-earnings ratio at its highest level since the dot-com bubble. That doesn't mean that investors should be selling all their stocks and waiting ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/19/3-stocks-to-add-to-your-portfolio-in-a-market-pull/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CMG":"墨式烧烤","V":"Visa","NVDA":"英伟达"},"source_url":"https://www.fool.com/investing/2021/09/19/3-stocks-to-add-to-your-portfolio-in-a-market-pull/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2168505605","content_text":"Stocks are expensive right now, with the S&P 500 price-to-earnings ratio at its highest level since the dot-com bubble. That doesn't mean that investors should be selling all their stocks and waiting for the next crash. It could be a while until a correction occurs, and that sort of strategy would have caused you to miss out on the past year of market growth.\nStill, some shrewd investors have built more defensive portfolios and are waiting for a pull-back to scoop up great companies that happen to have aggressive valuations right now. These three stocks are great opportunities that you should consider if they get any cheaper.\nNvidia\nNvidia (NASDAQ:NVDA) is a rockstar tech stock with outstanding growth catalysts, and it's returned more than 230% since the pandemic market bottom in March 2020.\nNVDA data by YCharts\nNvidia is the global market leader in PC graphics processor units (GPU), with 83% market share. The company supplies microchips that are essential for gaming, high-performance video, and other applications that require more advanced visual hardware. The global video game market is expected to grow more than 12% annually over the next five years, and high-resolution video content continues to become a preferred media for consumers. Those factors alone provide catalysts for Nvidia for the foreseeable future.\nHowever, Nvidia's opportunity isn't limited to gaming and personal computing. The company's chips have important applications in data centers, the automotive and autonomous vehicle industry, artificial intelligence and automation technology, and 5G network infrastructure. Connection to those trends provides an even more enticing growth opportunity.\nWhat's the catch here? Nvidia is expensive. Its forward price-to-earnings ratio of 55 is high relative to most other semiconductor stocks, and it's substantially higher than Nvidia's own recent historical levels. Even the PEG ratio, which takes into account the company's bullish growth forecast, indicates an expensive-looking stock.\nNVDA P/E Ratio (Forward 1y) data by YCharts\nOverall, it seems that Nvidia is a great stock to own, but there might be less expensive alternatives that can deliver better fundamentals for the price. If there's a market pull-back anytime soon, Nvidia should be one of the first stocks to consider at a lower price.\nImage source: Getty Images.\nChipotle\nChipotle Mexican Grill (NYSE:CMG) is a chain of well-known, fast-casual restaurants. The company has managed to endure a handful of scandals and an unprecedented pandemic, and it just keeps on growing. The chain's perceived value, nutrition, quality, and convenience clearly resonate with consumers. With double-digit growth forecast for this year and next, it doesn't seem like there's any reason to expect Chipotle to falter soon.\nChipotle has plenty of avenues for continued growth that excite investors. It has fewer than 2,900 locations, less than half of its sales are from its digital channel, and delivery services only produce 1% of total revenue. The company produces substantial cash flow, and the only debt on its balance sheet is related to operating lease obligations, not loans. That limits financial risk and means that Chipotle could easily source capital for growth if the need arose.\nOnce again, the issue here is really about valuation. Chipotle has often attracted aggressive valuation multiples, and its 56 forward P/E ratio seems more characteristic of a tech company than an established restaurant chain. Its enterprise-value-to-EBITDA ratio of 50 indicates that it's not a situation in which earnings per share misrepresent true profits. Chipotle is simply expensive to own. If the market gives you an opportunity to scoop up some shares at a more attractive price, it's worth consideration.\nVisa\nVisa (NYSE:V) is a household name with a brand that's nearly synonymous with credit and debit cards. People see that logo every day, and it's also featured on the front doors of countless restaurants and retailers that accept Visa cards. There's more going on under the surface here, too, and this company offers some exposure to a wider fintech revolution that's been occurring.\nVisa is really a payment processing network with global reach, rather than a credit card supplier. This is a rapidly evolving landscape with the likes of Square (NYSE:SQ), PayPal (NASDAQ:PYPL), countless ambitious start-ups, and various blockchain solutions springing up to bring efficiency and security to digital payments and transfers.\nVisa remains competitive by making acquisitions and creating partnerships with innovators that might otherwise turn into competitors. Regulators blocked its acquisition of Plaid, and Visa pivoted by purchasing the B2B cross-border payment platform Currencycloud and Tink, a European open-banking platform for consumers.\nVisa offers a compelling business narrative, but its value as an investment is a bit less straightforward. It's hard to consider this a value stock with a forward P/E ratio of 30.6 and a 0.6% dividend yield. Like many other stocks, Visa is near the high end of its recent range for the P/E ratio.\nV Normalized PE Ratio (Annual) data by YCharts\nOn the other hand, Visa is mature compared to other fintech stocks and doesn't have quite the same growth prospects. It's also in a tough spot as the incumbent power in an industry that's undergoing rapid evolution. If we have a market correction, Visa would suddenly look a lot better as a value investment with more upside than most. If the stock's price dips around 15%, its PEG ratio would creep toward 1.5. At that valuation, I would buy Visa hand over fist as a cash flow generator with uncommon growth potential.","news_type":1},"isVote":1,"tweetType":1,"viewCount":192,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":887097920,"gmtCreate":1631940583860,"gmtModify":1676530675150,"author":{"id":"3580436163482352","authorId":"3580436163482352","name":"JohnLoh00","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/887097920","repostId":"2168574191","repostType":4,"repost":{"id":"2168574191","pubTimestamp":1631928823,"share":"https://www.laohu8.com/m/news/2168574191?lang=&edition=full","pubTime":"2021-09-18 09:33","market":"us","language":"en","title":"Pfizer Covid-19 shot's protection against hospitalisation wanes in study","url":"https://stock-news.laohu8.com/highlight/detail?id=2168574191","media":"The Straits Times","summary":"WASHINGTON (BLOOMBERG) - Pfizer's Covid-19 vaccine declined in protection against hospitalisation af","content":"<div>\n<p>WASHINGTON (BLOOMBERG) - Pfizer's Covid-19 vaccine declined in protection against hospitalisation after four months, while Moderna's remained stable, US researchers found in an analysis of data from ...</p>\n\n<a href=\"http://www.straitstimes.com/world/united-states/pfizer-covid-19-shots-protection-against-hospitalisation-wanes-in-study\">Web Link</a>\n\n</div>\n","source":"straits_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Covid-19 shot's protection against hospitalisation wanes in study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Covid-19 shot's protection against hospitalisation wanes in study\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-18 09:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://www.straitstimes.com/world/united-states/pfizer-covid-19-shots-protection-against-hospitalisation-wanes-in-study><strong>The Straits Times</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>WASHINGTON (BLOOMBERG) - Pfizer's Covid-19 vaccine declined in protection against hospitalisation after four months, while Moderna's remained stable, US researchers found in an analysis of data from ...</p>\n\n<a href=\"http://www.straitstimes.com/world/united-states/pfizer-covid-19-shots-protection-against-hospitalisation-wanes-in-study\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"http://www.straitstimes.com/world/united-states/pfizer-covid-19-shots-protection-against-hospitalisation-wanes-in-study","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2168574191","content_text":"WASHINGTON (BLOOMBERG) - Pfizer's Covid-19 vaccine declined in protection against hospitalisation after four months, while Moderna's remained stable, US researchers found in an analysis of data from 21 US hospitals across 18 states.\nTwo doses of either vaccine provided more protection against hospitalisation than the one-dose Johnson & Johnson vaccine, the study found, though Pfizer's advantage over J&J narrowed over time, according to the study published on Friday (Sept 17) by the Centres for Disease Control and Prevention with collaborators across the country.\nAll three vaccines provided substantial protection after four months - Moderna's was 92 per cent effective against hospitalisation by then, with Pfizer's at 77 per cent and J&J at 68 per cent.\nThe data, published on Friday, may influence the debate over whether Americans should receive a third dose of vaccine to ward off the virus.\nAdvisers to the Food and Drug Administration are expected to vote on Friday on whether to recommend a booster shot, and they've mostly had to rely on data from Israel and the UK on whether the shots' effectiveness wanes over time.\nThe US is facing a surge of Covid-19 infections fuelled by the highly transmissible Delta variant, particularly among unvaccinated parts of the country, and breakthrough infections among vaccinated people have become more common.\nThe CDC study looked at 3,689 non-immunocompromised adults from March to August. The researchers noted that the vaccine effectiveness differences between Moderna and Pfizer's shots, which both use a mechanism called messenger RNA, could be due to differences in timings between doses.\nThe second dose of the Pfizer vaccine is typically delivered after three weeks, while Moderna patients wait four weeks.\nThey also noted several limitations to the study, including the fact that a relatively small number of patients had received the J&J vaccine compared with the mRNA vaccines.\nPrevious studies have found that Moderna's vaccine appears to generate more antibodies than Pfizer's, though it's not clear if antibodies are even the most important component in immunity over the long term.","news_type":1},"isVote":1,"tweetType":1,"viewCount":95,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":885045807,"gmtCreate":1631748395909,"gmtModify":1676530622670,"author":{"id":"3580436163482352","authorId":"3580436163482352","name":"JohnLoh00","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/885045807","repostId":"1121883775","repostType":4,"isVote":1,"tweetType":1,"viewCount":98,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":885045088,"gmtCreate":1631748377144,"gmtModify":1676530622661,"author":{"id":"3580436163482352","authorId":"3580436163482352","name":"JohnLoh00","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/885045088","repostId":"2167559884","repostType":4,"repost":{"id":"2167559884","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1631721822,"share":"https://www.laohu8.com/m/news/2167559884?lang=&edition=full","pubTime":"2021-09-16 00:03","market":"us","language":"en","title":"Procept BioRobotics spikes 40% on its first day of trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2167559884","media":"Dow Jones","summary":"Procept BioRobotics spikes 40% on its first day of trading.\n\nProcept BioRobotics Corp. is set to go ","content":"<p>Procept BioRobotics spikes 40% on its first day of trading.</p>\n<p><img src=\"https://static.tigerbbs.com/70f6e6c88567a43f408cd96f913f6476\" tg-width=\"1404\" tg-height=\"888\" width=\"100%\" height=\"auto\"></p>\n<p>Procept BioRobotics Corp.&nbsp;is set to go public Wednesday, as the California-based surgical robotics company's upsized initial public offering priced above the expected range at $25.00 per share. The company sold 6.56 million shares in the IPO to raise $163.9 million. Procept had previously expected to offer 5.5 million shares in the IPO, which was projected to price between $22 and $24 per share. The stock is expected to begin trading Wednesday on the Nasdaq under the ticker symbol \"PRCT.\" With 41.21 million shares outstanding after the IPO, the pricing values Procept at $1.03 billion. BofA Securities and Goldman Sachs are the joint lead bookrunning managers. The company had recorded a net loss of $27.4 million on revenue of $15.7 million in the six months ended June 30, after a loss of $25.7 million on revenue of $2.4 million in the same period a year ago. The company is going public at a time that the <a href=\"https://laohu8.com/S/IPO\">Renaissance IPO ETF</a>&nbsp;has gained 7.4% over the past three months while the S&amp;P 500 has tacked on 4.6%.</p>\n<p><b>Company and Technology</b></p>\n<p>Redwood City, California-based Procept was founded to develop advanced surgical robotic devices for use in minimally invasive procedures.</p>\n<p>Management is headed by President and CEO Reza Zadno, Ph.D., who has been with the firm since February 2020 and was previously president and CEO of Avedro, a healthcare company.</p>\n<p>The company's first instrument is the AquaBeam Robotic System for use in urologic surgery with an initial focus on treating benign prostate hyperplasia.</p>\n<p>Procept has received at least $328 million in equity investment from investors including CPMG, Viking Global, Fidelity and individuals.</p>\n<p>Customer Acquisition</p>\n<p>The firm sells its product to hospitals who in turn charge various third party payors for each service rendered.</p>\n<p>The company is targeting 860 high-volume hospitals which account for 70% of all hospital-based resective procedures.</p>\n<p>Selling, G&amp;A expenses as a percentage of total revenue have dropped substantially as revenues have increased, as the figures below indicate:</p>\n<table>\n <colgroup></colgroup>\n <tbody>\n  <tr>\n   <td><p><b>Selling, G&amp;A</b></p></td>\n   <td><p><b>Expenses vs. Revenue</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Percentage</p></td>\n  </tr>\n  <tr>\n   <td><p>Six Mos. Ended June 30, 2021</p></td>\n   <td><p>144.5%</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>392.3%</p></td>\n  </tr>\n  <tr>\n   <td><p>2019</p></td>\n   <td><p>462.3%</p></td>\n  </tr>\n </tbody>\n</table>\n<p>The Selling, G&amp;A efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Selling, G&amp;A spend, rose to 0.6x in the most recent reporting period, as shown in the table below:</p>\n<table>\n <colgroup></colgroup>\n <tbody>\n  <tr>\n   <td><p><b>Selling, G&amp;A</b></p></td>\n   <td><p><b>Efficiency Rate</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Multiple</p></td>\n  </tr>\n  <tr>\n   <td><p>Six Mos. Ended June 30, 2021</p></td>\n   <td><p>0.6</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>0.1</p></td>\n  </tr>\n </tbody>\n</table>\n<p><b>Market &amp; Competition</b></p>\n<p>According to a 2018 marketresearch reportby Allied Market Research, the global market for treating benign prostatic hyperplasia was an estimated $10.7 billion in 2017 and is forecast to reach $20.1 billion by 2025.</p>\n<p>This represents a forecast CAGR of 8.1% from 2018 to 2025.</p>\n<p>The main drivers for this expected growth are an increase in disease incidence to the aging of the global population of males.</p>\n<p>Also, alpha-blocker drugs are likely to be a major competitor, as they help in relaxing the muscle of the prostate and the bladder neck, allowing urination to occur more easily.</p>\n<p>Major competitive or other industry participants include:</p>\n<ul>\n <li>Boehringer Ingelheim</li>\n <li>Allergan</li>\n <li>GlaxoSmithKline(NYSE:GSK)</li>\n <li>Merck(NYSE:MRK)</li>\n <li>Teleflex(NYSE:TFX)</li>\n <li>Boston Scientific(NYSE:BSX)</li>\n <li>Others</li>\n</ul>\n<p><b>Financial Performance</b></p>\n<p>Procept’s recent financial results can be summarized as follows:</p>\n<ul>\n <li>Sharply growing top-line revenue from a small base</li>\n <li>A swing to gross profit and positive gross margin</li>\n <li>High and increasing operating losses</li>\n <li>High and increasing cash used in operations</li>\n</ul>\n<p>Below are relevant financial results derived from the firm’s registration statement:</p>\n<p><img src=\"https://static.tigerbbs.com/6fb31b91e96ed681b39c952c72b32105\" tg-width=\"904\" tg-height=\"439\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/94b04bc1fd096b33535887c4c77d17a5\" tg-width=\"906\" tg-height=\"442\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/72b3c6e00fbb7d021141642eb8f69104\" tg-width=\"907\" tg-height=\"441\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/43410c6bd6487d96c4424db32f9c94e7\" tg-width=\"907\" tg-height=\"438\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/0457da194f7ee652bf4bad3deb6fbf40\" tg-width=\"908\" tg-height=\"441\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/12ac204e8226347ff04eb9ca845142aa\" tg-width=\"902\" tg-height=\"439\" referrerpolicy=\"no-referrer\"></p>\n<p>As of June 30, 2021, Procept had $159.2 million in cash and $68.3 million in total liabilities.</p>\n<p>Free cash flow during the twelve months ended June 30, 2021, was negative ($52.7 million).</p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Procept BioRobotics spikes 40% on its first day of trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nProcept BioRobotics spikes 40% on its first day of trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-09-16 00:03</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Procept BioRobotics spikes 40% on its first day of trading.</p>\n<p><img src=\"https://static.tigerbbs.com/70f6e6c88567a43f408cd96f913f6476\" tg-width=\"1404\" tg-height=\"888\" width=\"100%\" height=\"auto\"></p>\n<p>Procept BioRobotics Corp.&nbsp;is set to go public Wednesday, as the California-based surgical robotics company's upsized initial public offering priced above the expected range at $25.00 per share. The company sold 6.56 million shares in the IPO to raise $163.9 million. Procept had previously expected to offer 5.5 million shares in the IPO, which was projected to price between $22 and $24 per share. The stock is expected to begin trading Wednesday on the Nasdaq under the ticker symbol \"PRCT.\" With 41.21 million shares outstanding after the IPO, the pricing values Procept at $1.03 billion. BofA Securities and Goldman Sachs are the joint lead bookrunning managers. The company had recorded a net loss of $27.4 million on revenue of $15.7 million in the six months ended June 30, after a loss of $25.7 million on revenue of $2.4 million in the same period a year ago. The company is going public at a time that the <a href=\"https://laohu8.com/S/IPO\">Renaissance IPO ETF</a>&nbsp;has gained 7.4% over the past three months while the S&amp;P 500 has tacked on 4.6%.</p>\n<p><b>Company and Technology</b></p>\n<p>Redwood City, California-based Procept was founded to develop advanced surgical robotic devices for use in minimally invasive procedures.</p>\n<p>Management is headed by President and CEO Reza Zadno, Ph.D., who has been with the firm since February 2020 and was previously president and CEO of Avedro, a healthcare company.</p>\n<p>The company's first instrument is the AquaBeam Robotic System for use in urologic surgery with an initial focus on treating benign prostate hyperplasia.</p>\n<p>Procept has received at least $328 million in equity investment from investors including CPMG, Viking Global, Fidelity and individuals.</p>\n<p>Customer Acquisition</p>\n<p>The firm sells its product to hospitals who in turn charge various third party payors for each service rendered.</p>\n<p>The company is targeting 860 high-volume hospitals which account for 70% of all hospital-based resective procedures.</p>\n<p>Selling, G&amp;A expenses as a percentage of total revenue have dropped substantially as revenues have increased, as the figures below indicate:</p>\n<table>\n <colgroup></colgroup>\n <tbody>\n  <tr>\n   <td><p><b>Selling, G&amp;A</b></p></td>\n   <td><p><b>Expenses vs. Revenue</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Percentage</p></td>\n  </tr>\n  <tr>\n   <td><p>Six Mos. Ended June 30, 2021</p></td>\n   <td><p>144.5%</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>392.3%</p></td>\n  </tr>\n  <tr>\n   <td><p>2019</p></td>\n   <td><p>462.3%</p></td>\n  </tr>\n </tbody>\n</table>\n<p>The Selling, G&amp;A efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Selling, G&amp;A spend, rose to 0.6x in the most recent reporting period, as shown in the table below:</p>\n<table>\n <colgroup></colgroup>\n <tbody>\n  <tr>\n   <td><p><b>Selling, G&amp;A</b></p></td>\n   <td><p><b>Efficiency Rate</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Multiple</p></td>\n  </tr>\n  <tr>\n   <td><p>Six Mos. Ended June 30, 2021</p></td>\n   <td><p>0.6</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>0.1</p></td>\n  </tr>\n </tbody>\n</table>\n<p><b>Market &amp; Competition</b></p>\n<p>According to a 2018 marketresearch reportby Allied Market Research, the global market for treating benign prostatic hyperplasia was an estimated $10.7 billion in 2017 and is forecast to reach $20.1 billion by 2025.</p>\n<p>This represents a forecast CAGR of 8.1% from 2018 to 2025.</p>\n<p>The main drivers for this expected growth are an increase in disease incidence to the aging of the global population of males.</p>\n<p>Also, alpha-blocker drugs are likely to be a major competitor, as they help in relaxing the muscle of the prostate and the bladder neck, allowing urination to occur more easily.</p>\n<p>Major competitive or other industry participants include:</p>\n<ul>\n <li>Boehringer Ingelheim</li>\n <li>Allergan</li>\n <li>GlaxoSmithKline(NYSE:GSK)</li>\n <li>Merck(NYSE:MRK)</li>\n <li>Teleflex(NYSE:TFX)</li>\n <li>Boston Scientific(NYSE:BSX)</li>\n <li>Others</li>\n</ul>\n<p><b>Financial Performance</b></p>\n<p>Procept’s recent financial results can be summarized as follows:</p>\n<ul>\n <li>Sharply growing top-line revenue from a small base</li>\n <li>A swing to gross profit and positive gross margin</li>\n <li>High and increasing operating losses</li>\n <li>High and increasing cash used in operations</li>\n</ul>\n<p>Below are relevant financial results derived from the firm’s registration statement:</p>\n<p><img src=\"https://static.tigerbbs.com/6fb31b91e96ed681b39c952c72b32105\" tg-width=\"904\" tg-height=\"439\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/94b04bc1fd096b33535887c4c77d17a5\" tg-width=\"906\" tg-height=\"442\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/72b3c6e00fbb7d021141642eb8f69104\" tg-width=\"907\" tg-height=\"441\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/43410c6bd6487d96c4424db32f9c94e7\" tg-width=\"907\" tg-height=\"438\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/0457da194f7ee652bf4bad3deb6fbf40\" tg-width=\"908\" tg-height=\"441\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/12ac204e8226347ff04eb9ca845142aa\" tg-width=\"902\" tg-height=\"439\" referrerpolicy=\"no-referrer\"></p>\n<p>As of June 30, 2021, Procept had $159.2 million in cash and $68.3 million in total liabilities.</p>\n<p>Free cash flow during the twelve months ended June 30, 2021, was negative ($52.7 million).</p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PRCT":"PROCEPT BioRobotics"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2167559884","content_text":"Procept BioRobotics spikes 40% on its first day of trading.\n\nProcept BioRobotics Corp. is set to go public Wednesday, as the California-based surgical robotics company's upsized initial public offering priced above the expected range at $25.00 per share. The company sold 6.56 million shares in the IPO to raise $163.9 million. Procept had previously expected to offer 5.5 million shares in the IPO, which was projected to price between $22 and $24 per share. The stock is expected to begin trading Wednesday on the Nasdaq under the ticker symbol \"PRCT.\" With 41.21 million shares outstanding after the IPO, the pricing values Procept at $1.03 billion. BofA Securities and Goldman Sachs are the joint lead bookrunning managers. The company had recorded a net loss of $27.4 million on revenue of $15.7 million in the six months ended June 30, after a loss of $25.7 million on revenue of $2.4 million in the same period a year ago. The company is going public at a time that the Renaissance IPO ETF has gained 7.4% over the past three months while the S&P 500 has tacked on 4.6%.\nCompany and Technology\nRedwood City, California-based Procept was founded to develop advanced surgical robotic devices for use in minimally invasive procedures.\nManagement is headed by President and CEO Reza Zadno, Ph.D., who has been with the firm since February 2020 and was previously president and CEO of Avedro, a healthcare company.\nThe company's first instrument is the AquaBeam Robotic System for use in urologic surgery with an initial focus on treating benign prostate hyperplasia.\nProcept has received at least $328 million in equity investment from investors including CPMG, Viking Global, Fidelity and individuals.\nCustomer Acquisition\nThe firm sells its product to hospitals who in turn charge various third party payors for each service rendered.\nThe company is targeting 860 high-volume hospitals which account for 70% of all hospital-based resective procedures.\nSelling, G&A expenses as a percentage of total revenue have dropped substantially as revenues have increased, as the figures below indicate:\n\n\n\n\nSelling, G&A\nExpenses vs. Revenue\n\n\nPeriod\nPercentage\n\n\nSix Mos. Ended June 30, 2021\n144.5%\n\n\n2020\n392.3%\n\n\n2019\n462.3%\n\n\n\nThe Selling, G&A efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Selling, G&A spend, rose to 0.6x in the most recent reporting period, as shown in the table below:\n\n\n\n\nSelling, G&A\nEfficiency Rate\n\n\nPeriod\nMultiple\n\n\nSix Mos. Ended June 30, 2021\n0.6\n\n\n2020\n0.1\n\n\n\nMarket & Competition\nAccording to a 2018 marketresearch reportby Allied Market Research, the global market for treating benign prostatic hyperplasia was an estimated $10.7 billion in 2017 and is forecast to reach $20.1 billion by 2025.\nThis represents a forecast CAGR of 8.1% from 2018 to 2025.\nThe main drivers for this expected growth are an increase in disease incidence to the aging of the global population of males.\nAlso, alpha-blocker drugs are likely to be a major competitor, as they help in relaxing the muscle of the prostate and the bladder neck, allowing urination to occur more easily.\nMajor competitive or other industry participants include:\n\nBoehringer Ingelheim\nAllergan\nGlaxoSmithKline(NYSE:GSK)\nMerck(NYSE:MRK)\nTeleflex(NYSE:TFX)\nBoston Scientific(NYSE:BSX)\nOthers\n\nFinancial Performance\nProcept’s recent financial results can be summarized as follows:\n\nSharply growing top-line revenue from a small base\nA swing to gross profit and positive gross margin\nHigh and increasing operating losses\nHigh and increasing cash used in operations\n\nBelow are relevant financial results derived from the firm’s registration statement:\n\nAs of June 30, 2021, Procept had $159.2 million in cash and $68.3 million in total liabilities.\nFree cash flow during the twelve months ended June 30, 2021, was negative ($52.7 million).","news_type":1},"isVote":1,"tweetType":1,"viewCount":250,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":885042243,"gmtCreate":1631748359982,"gmtModify":1676530622638,"author":{"id":"3580436163482352","authorId":"3580436163482352","name":"JohnLoh00","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/885042243","repostId":"2167559884","repostType":4,"repost":{"id":"2167559884","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1631721822,"share":"https://www.laohu8.com/m/news/2167559884?lang=&edition=full","pubTime":"2021-09-16 00:03","market":"us","language":"en","title":"Procept BioRobotics spikes 40% on its first day of trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2167559884","media":"Dow Jones","summary":"Procept BioRobotics spikes 40% on its first day of trading.\n\nProcept BioRobotics Corp. is set to go ","content":"<p>Procept BioRobotics spikes 40% on its first day of trading.</p>\n<p><img src=\"https://static.tigerbbs.com/70f6e6c88567a43f408cd96f913f6476\" tg-width=\"1404\" tg-height=\"888\" width=\"100%\" height=\"auto\"></p>\n<p>Procept BioRobotics Corp.&nbsp;is set to go public Wednesday, as the California-based surgical robotics company's upsized initial public offering priced above the expected range at $25.00 per share. The company sold 6.56 million shares in the IPO to raise $163.9 million. Procept had previously expected to offer 5.5 million shares in the IPO, which was projected to price between $22 and $24 per share. The stock is expected to begin trading Wednesday on the Nasdaq under the ticker symbol \"PRCT.\" With 41.21 million shares outstanding after the IPO, the pricing values Procept at $1.03 billion. BofA Securities and Goldman Sachs are the joint lead bookrunning managers. The company had recorded a net loss of $27.4 million on revenue of $15.7 million in the six months ended June 30, after a loss of $25.7 million on revenue of $2.4 million in the same period a year ago. The company is going public at a time that the <a href=\"https://laohu8.com/S/IPO\">Renaissance IPO ETF</a>&nbsp;has gained 7.4% over the past three months while the S&amp;P 500 has tacked on 4.6%.</p>\n<p><b>Company and Technology</b></p>\n<p>Redwood City, California-based Procept was founded to develop advanced surgical robotic devices for use in minimally invasive procedures.</p>\n<p>Management is headed by President and CEO Reza Zadno, Ph.D., who has been with the firm since February 2020 and was previously president and CEO of Avedro, a healthcare company.</p>\n<p>The company's first instrument is the AquaBeam Robotic System for use in urologic surgery with an initial focus on treating benign prostate hyperplasia.</p>\n<p>Procept has received at least $328 million in equity investment from investors including CPMG, Viking Global, Fidelity and individuals.</p>\n<p>Customer Acquisition</p>\n<p>The firm sells its product to hospitals who in turn charge various third party payors for each service rendered.</p>\n<p>The company is targeting 860 high-volume hospitals which account for 70% of all hospital-based resective procedures.</p>\n<p>Selling, G&amp;A expenses as a percentage of total revenue have dropped substantially as revenues have increased, as the figures below indicate:</p>\n<table>\n <colgroup></colgroup>\n <tbody>\n  <tr>\n   <td><p><b>Selling, G&amp;A</b></p></td>\n   <td><p><b>Expenses vs. Revenue</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Percentage</p></td>\n  </tr>\n  <tr>\n   <td><p>Six Mos. Ended June 30, 2021</p></td>\n   <td><p>144.5%</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>392.3%</p></td>\n  </tr>\n  <tr>\n   <td><p>2019</p></td>\n   <td><p>462.3%</p></td>\n  </tr>\n </tbody>\n</table>\n<p>The Selling, G&amp;A efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Selling, G&amp;A spend, rose to 0.6x in the most recent reporting period, as shown in the table below:</p>\n<table>\n <colgroup></colgroup>\n <tbody>\n  <tr>\n   <td><p><b>Selling, G&amp;A</b></p></td>\n   <td><p><b>Efficiency Rate</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Multiple</p></td>\n  </tr>\n  <tr>\n   <td><p>Six Mos. Ended June 30, 2021</p></td>\n   <td><p>0.6</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>0.1</p></td>\n  </tr>\n </tbody>\n</table>\n<p><b>Market &amp; Competition</b></p>\n<p>According to a 2018 marketresearch reportby Allied Market Research, the global market for treating benign prostatic hyperplasia was an estimated $10.7 billion in 2017 and is forecast to reach $20.1 billion by 2025.</p>\n<p>This represents a forecast CAGR of 8.1% from 2018 to 2025.</p>\n<p>The main drivers for this expected growth are an increase in disease incidence to the aging of the global population of males.</p>\n<p>Also, alpha-blocker drugs are likely to be a major competitor, as they help in relaxing the muscle of the prostate and the bladder neck, allowing urination to occur more easily.</p>\n<p>Major competitive or other industry participants include:</p>\n<ul>\n <li>Boehringer Ingelheim</li>\n <li>Allergan</li>\n <li>GlaxoSmithKline(NYSE:GSK)</li>\n <li>Merck(NYSE:MRK)</li>\n <li>Teleflex(NYSE:TFX)</li>\n <li>Boston Scientific(NYSE:BSX)</li>\n <li>Others</li>\n</ul>\n<p><b>Financial Performance</b></p>\n<p>Procept’s recent financial results can be summarized as follows:</p>\n<ul>\n <li>Sharply growing top-line revenue from a small base</li>\n <li>A swing to gross profit and positive gross margin</li>\n <li>High and increasing operating losses</li>\n <li>High and increasing cash used in operations</li>\n</ul>\n<p>Below are relevant financial results derived from the firm’s registration statement:</p>\n<p><img src=\"https://static.tigerbbs.com/6fb31b91e96ed681b39c952c72b32105\" tg-width=\"904\" tg-height=\"439\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/94b04bc1fd096b33535887c4c77d17a5\" tg-width=\"906\" tg-height=\"442\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/72b3c6e00fbb7d021141642eb8f69104\" tg-width=\"907\" tg-height=\"441\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/43410c6bd6487d96c4424db32f9c94e7\" tg-width=\"907\" tg-height=\"438\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/0457da194f7ee652bf4bad3deb6fbf40\" tg-width=\"908\" tg-height=\"441\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/12ac204e8226347ff04eb9ca845142aa\" tg-width=\"902\" tg-height=\"439\" referrerpolicy=\"no-referrer\"></p>\n<p>As of June 30, 2021, Procept had $159.2 million in cash and $68.3 million in total liabilities.</p>\n<p>Free cash flow during the twelve months ended June 30, 2021, was negative ($52.7 million).</p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Procept BioRobotics spikes 40% on its first day of trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nProcept BioRobotics spikes 40% on its first day of trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-09-16 00:03</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Procept BioRobotics spikes 40% on its first day of trading.</p>\n<p><img src=\"https://static.tigerbbs.com/70f6e6c88567a43f408cd96f913f6476\" tg-width=\"1404\" tg-height=\"888\" width=\"100%\" height=\"auto\"></p>\n<p>Procept BioRobotics Corp.&nbsp;is set to go public Wednesday, as the California-based surgical robotics company's upsized initial public offering priced above the expected range at $25.00 per share. The company sold 6.56 million shares in the IPO to raise $163.9 million. Procept had previously expected to offer 5.5 million shares in the IPO, which was projected to price between $22 and $24 per share. The stock is expected to begin trading Wednesday on the Nasdaq under the ticker symbol \"PRCT.\" With 41.21 million shares outstanding after the IPO, the pricing values Procept at $1.03 billion. BofA Securities and Goldman Sachs are the joint lead bookrunning managers. The company had recorded a net loss of $27.4 million on revenue of $15.7 million in the six months ended June 30, after a loss of $25.7 million on revenue of $2.4 million in the same period a year ago. The company is going public at a time that the <a href=\"https://laohu8.com/S/IPO\">Renaissance IPO ETF</a>&nbsp;has gained 7.4% over the past three months while the S&amp;P 500 has tacked on 4.6%.</p>\n<p><b>Company and Technology</b></p>\n<p>Redwood City, California-based Procept was founded to develop advanced surgical robotic devices for use in minimally invasive procedures.</p>\n<p>Management is headed by President and CEO Reza Zadno, Ph.D., who has been with the firm since February 2020 and was previously president and CEO of Avedro, a healthcare company.</p>\n<p>The company's first instrument is the AquaBeam Robotic System for use in urologic surgery with an initial focus on treating benign prostate hyperplasia.</p>\n<p>Procept has received at least $328 million in equity investment from investors including CPMG, Viking Global, Fidelity and individuals.</p>\n<p>Customer Acquisition</p>\n<p>The firm sells its product to hospitals who in turn charge various third party payors for each service rendered.</p>\n<p>The company is targeting 860 high-volume hospitals which account for 70% of all hospital-based resective procedures.</p>\n<p>Selling, G&amp;A expenses as a percentage of total revenue have dropped substantially as revenues have increased, as the figures below indicate:</p>\n<table>\n <colgroup></colgroup>\n <tbody>\n  <tr>\n   <td><p><b>Selling, G&amp;A</b></p></td>\n   <td><p><b>Expenses vs. Revenue</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Percentage</p></td>\n  </tr>\n  <tr>\n   <td><p>Six Mos. Ended June 30, 2021</p></td>\n   <td><p>144.5%</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>392.3%</p></td>\n  </tr>\n  <tr>\n   <td><p>2019</p></td>\n   <td><p>462.3%</p></td>\n  </tr>\n </tbody>\n</table>\n<p>The Selling, G&amp;A efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Selling, G&amp;A spend, rose to 0.6x in the most recent reporting period, as shown in the table below:</p>\n<table>\n <colgroup></colgroup>\n <tbody>\n  <tr>\n   <td><p><b>Selling, G&amp;A</b></p></td>\n   <td><p><b>Efficiency Rate</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Multiple</p></td>\n  </tr>\n  <tr>\n   <td><p>Six Mos. Ended June 30, 2021</p></td>\n   <td><p>0.6</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>0.1</p></td>\n  </tr>\n </tbody>\n</table>\n<p><b>Market &amp; Competition</b></p>\n<p>According to a 2018 marketresearch reportby Allied Market Research, the global market for treating benign prostatic hyperplasia was an estimated $10.7 billion in 2017 and is forecast to reach $20.1 billion by 2025.</p>\n<p>This represents a forecast CAGR of 8.1% from 2018 to 2025.</p>\n<p>The main drivers for this expected growth are an increase in disease incidence to the aging of the global population of males.</p>\n<p>Also, alpha-blocker drugs are likely to be a major competitor, as they help in relaxing the muscle of the prostate and the bladder neck, allowing urination to occur more easily.</p>\n<p>Major competitive or other industry participants include:</p>\n<ul>\n <li>Boehringer Ingelheim</li>\n <li>Allergan</li>\n <li>GlaxoSmithKline(NYSE:GSK)</li>\n <li>Merck(NYSE:MRK)</li>\n <li>Teleflex(NYSE:TFX)</li>\n <li>Boston Scientific(NYSE:BSX)</li>\n <li>Others</li>\n</ul>\n<p><b>Financial Performance</b></p>\n<p>Procept’s recent financial results can be summarized as follows:</p>\n<ul>\n <li>Sharply growing top-line revenue from a small base</li>\n <li>A swing to gross profit and positive gross margin</li>\n <li>High and increasing operating losses</li>\n <li>High and increasing cash used in operations</li>\n</ul>\n<p>Below are relevant financial results derived from the firm’s registration statement:</p>\n<p><img src=\"https://static.tigerbbs.com/6fb31b91e96ed681b39c952c72b32105\" tg-width=\"904\" tg-height=\"439\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/94b04bc1fd096b33535887c4c77d17a5\" tg-width=\"906\" tg-height=\"442\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/72b3c6e00fbb7d021141642eb8f69104\" tg-width=\"907\" tg-height=\"441\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/43410c6bd6487d96c4424db32f9c94e7\" tg-width=\"907\" tg-height=\"438\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/0457da194f7ee652bf4bad3deb6fbf40\" tg-width=\"908\" tg-height=\"441\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/12ac204e8226347ff04eb9ca845142aa\" tg-width=\"902\" tg-height=\"439\" referrerpolicy=\"no-referrer\"></p>\n<p>As of June 30, 2021, Procept had $159.2 million in cash and $68.3 million in total liabilities.</p>\n<p>Free cash flow during the twelve months ended June 30, 2021, was negative ($52.7 million).</p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PRCT":"PROCEPT BioRobotics"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2167559884","content_text":"Procept BioRobotics spikes 40% on its first day of trading.\n\nProcept BioRobotics Corp. is set to go public Wednesday, as the California-based surgical robotics company's upsized initial public offering priced above the expected range at $25.00 per share. The company sold 6.56 million shares in the IPO to raise $163.9 million. Procept had previously expected to offer 5.5 million shares in the IPO, which was projected to price between $22 and $24 per share. The stock is expected to begin trading Wednesday on the Nasdaq under the ticker symbol \"PRCT.\" With 41.21 million shares outstanding after the IPO, the pricing values Procept at $1.03 billion. BofA Securities and Goldman Sachs are the joint lead bookrunning managers. The company had recorded a net loss of $27.4 million on revenue of $15.7 million in the six months ended June 30, after a loss of $25.7 million on revenue of $2.4 million in the same period a year ago. The company is going public at a time that the Renaissance IPO ETF has gained 7.4% over the past three months while the S&P 500 has tacked on 4.6%.\nCompany and Technology\nRedwood City, California-based Procept was founded to develop advanced surgical robotic devices for use in minimally invasive procedures.\nManagement is headed by President and CEO Reza Zadno, Ph.D., who has been with the firm since February 2020 and was previously president and CEO of Avedro, a healthcare company.\nThe company's first instrument is the AquaBeam Robotic System for use in urologic surgery with an initial focus on treating benign prostate hyperplasia.\nProcept has received at least $328 million in equity investment from investors including CPMG, Viking Global, Fidelity and individuals.\nCustomer Acquisition\nThe firm sells its product to hospitals who in turn charge various third party payors for each service rendered.\nThe company is targeting 860 high-volume hospitals which account for 70% of all hospital-based resective procedures.\nSelling, G&A expenses as a percentage of total revenue have dropped substantially as revenues have increased, as the figures below indicate:\n\n\n\n\nSelling, G&A\nExpenses vs. Revenue\n\n\nPeriod\nPercentage\n\n\nSix Mos. Ended June 30, 2021\n144.5%\n\n\n2020\n392.3%\n\n\n2019\n462.3%\n\n\n\nThe Selling, G&A efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Selling, G&A spend, rose to 0.6x in the most recent reporting period, as shown in the table below:\n\n\n\n\nSelling, G&A\nEfficiency Rate\n\n\nPeriod\nMultiple\n\n\nSix Mos. Ended June 30, 2021\n0.6\n\n\n2020\n0.1\n\n\n\nMarket & Competition\nAccording to a 2018 marketresearch reportby Allied Market Research, the global market for treating benign prostatic hyperplasia was an estimated $10.7 billion in 2017 and is forecast to reach $20.1 billion by 2025.\nThis represents a forecast CAGR of 8.1% from 2018 to 2025.\nThe main drivers for this expected growth are an increase in disease incidence to the aging of the global population of males.\nAlso, alpha-blocker drugs are likely to be a major competitor, as they help in relaxing the muscle of the prostate and the bladder neck, allowing urination to occur more easily.\nMajor competitive or other industry participants include:\n\nBoehringer Ingelheim\nAllergan\nGlaxoSmithKline(NYSE:GSK)\nMerck(NYSE:MRK)\nTeleflex(NYSE:TFX)\nBoston Scientific(NYSE:BSX)\nOthers\n\nFinancial Performance\nProcept’s recent financial results can be summarized as follows:\n\nSharply growing top-line revenue from a small base\nA swing to gross profit and positive gross margin\nHigh and increasing operating losses\nHigh and increasing cash used in operations\n\nBelow are relevant financial results derived from the firm’s registration statement:\n\nAs of June 30, 2021, Procept had $159.2 million in cash and $68.3 million in total liabilities.\nFree cash flow during the twelve months ended June 30, 2021, was negative ($52.7 million).","news_type":1},"isVote":1,"tweetType":1,"viewCount":139,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":882896308,"gmtCreate":1631671667604,"gmtModify":1676530605216,"author":{"id":"3580436163482352","authorId":"3580436163482352","name":"JohnLoh00","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/882896308","repostId":"1194314814","repostType":4,"isVote":1,"tweetType":1,"viewCount":35,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":860401147,"gmtCreate":1632193476289,"gmtModify":1676530722508,"author":{"id":"3580436163482352","authorId":"3580436163482352","name":"JohnLoh00","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/860401147","repostId":"1159687756","repostType":4,"isVote":1,"tweetType":1,"viewCount":176,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":860067721,"gmtCreate":1632108948463,"gmtModify":1676530702855,"author":{"id":"3580436163482352","authorId":"3580436163482352","name":"JohnLoh00","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/860067721","repostId":"2168505605","repostType":4,"isVote":1,"tweetType":1,"viewCount":192,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":887097920,"gmtCreate":1631940583860,"gmtModify":1676530675150,"author":{"id":"3580436163482352","authorId":"3580436163482352","name":"JohnLoh00","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/887097920","repostId":"2168574191","repostType":4,"isVote":1,"tweetType":1,"viewCount":95,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":885045088,"gmtCreate":1631748377144,"gmtModify":1676530622661,"author":{"id":"3580436163482352","authorId":"3580436163482352","name":"JohnLoh00","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/885045088","repostId":"2167559884","repostType":4,"repost":{"id":"2167559884","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1631721822,"share":"https://www.laohu8.com/m/news/2167559884?lang=&edition=full","pubTime":"2021-09-16 00:03","market":"us","language":"en","title":"Procept BioRobotics spikes 40% on its first day of trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2167559884","media":"Dow Jones","summary":"Procept BioRobotics spikes 40% on its first day of trading.\n\nProcept BioRobotics Corp. is set to go ","content":"<p>Procept BioRobotics spikes 40% on its first day of trading.</p>\n<p><img src=\"https://static.tigerbbs.com/70f6e6c88567a43f408cd96f913f6476\" tg-width=\"1404\" tg-height=\"888\" width=\"100%\" height=\"auto\"></p>\n<p>Procept BioRobotics Corp.&nbsp;is set to go public Wednesday, as the California-based surgical robotics company's upsized initial public offering priced above the expected range at $25.00 per share. The company sold 6.56 million shares in the IPO to raise $163.9 million. Procept had previously expected to offer 5.5 million shares in the IPO, which was projected to price between $22 and $24 per share. The stock is expected to begin trading Wednesday on the Nasdaq under the ticker symbol \"PRCT.\" With 41.21 million shares outstanding after the IPO, the pricing values Procept at $1.03 billion. BofA Securities and Goldman Sachs are the joint lead bookrunning managers. The company had recorded a net loss of $27.4 million on revenue of $15.7 million in the six months ended June 30, after a loss of $25.7 million on revenue of $2.4 million in the same period a year ago. The company is going public at a time that the <a href=\"https://laohu8.com/S/IPO\">Renaissance IPO ETF</a>&nbsp;has gained 7.4% over the past three months while the S&amp;P 500 has tacked on 4.6%.</p>\n<p><b>Company and Technology</b></p>\n<p>Redwood City, California-based Procept was founded to develop advanced surgical robotic devices for use in minimally invasive procedures.</p>\n<p>Management is headed by President and CEO Reza Zadno, Ph.D., who has been with the firm since February 2020 and was previously president and CEO of Avedro, a healthcare company.</p>\n<p>The company's first instrument is the AquaBeam Robotic System for use in urologic surgery with an initial focus on treating benign prostate hyperplasia.</p>\n<p>Procept has received at least $328 million in equity investment from investors including CPMG, Viking Global, Fidelity and individuals.</p>\n<p>Customer Acquisition</p>\n<p>The firm sells its product to hospitals who in turn charge various third party payors for each service rendered.</p>\n<p>The company is targeting 860 high-volume hospitals which account for 70% of all hospital-based resective procedures.</p>\n<p>Selling, G&amp;A expenses as a percentage of total revenue have dropped substantially as revenues have increased, as the figures below indicate:</p>\n<table>\n <colgroup></colgroup>\n <tbody>\n  <tr>\n   <td><p><b>Selling, G&amp;A</b></p></td>\n   <td><p><b>Expenses vs. Revenue</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Percentage</p></td>\n  </tr>\n  <tr>\n   <td><p>Six Mos. Ended June 30, 2021</p></td>\n   <td><p>144.5%</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>392.3%</p></td>\n  </tr>\n  <tr>\n   <td><p>2019</p></td>\n   <td><p>462.3%</p></td>\n  </tr>\n </tbody>\n</table>\n<p>The Selling, G&amp;A efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Selling, G&amp;A spend, rose to 0.6x in the most recent reporting period, as shown in the table below:</p>\n<table>\n <colgroup></colgroup>\n <tbody>\n  <tr>\n   <td><p><b>Selling, G&amp;A</b></p></td>\n   <td><p><b>Efficiency Rate</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Multiple</p></td>\n  </tr>\n  <tr>\n   <td><p>Six Mos. Ended June 30, 2021</p></td>\n   <td><p>0.6</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>0.1</p></td>\n  </tr>\n </tbody>\n</table>\n<p><b>Market &amp; Competition</b></p>\n<p>According to a 2018 marketresearch reportby Allied Market Research, the global market for treating benign prostatic hyperplasia was an estimated $10.7 billion in 2017 and is forecast to reach $20.1 billion by 2025.</p>\n<p>This represents a forecast CAGR of 8.1% from 2018 to 2025.</p>\n<p>The main drivers for this expected growth are an increase in disease incidence to the aging of the global population of males.</p>\n<p>Also, alpha-blocker drugs are likely to be a major competitor, as they help in relaxing the muscle of the prostate and the bladder neck, allowing urination to occur more easily.</p>\n<p>Major competitive or other industry participants include:</p>\n<ul>\n <li>Boehringer Ingelheim</li>\n <li>Allergan</li>\n <li>GlaxoSmithKline(NYSE:GSK)</li>\n <li>Merck(NYSE:MRK)</li>\n <li>Teleflex(NYSE:TFX)</li>\n <li>Boston Scientific(NYSE:BSX)</li>\n <li>Others</li>\n</ul>\n<p><b>Financial Performance</b></p>\n<p>Procept’s recent financial results can be summarized as follows:</p>\n<ul>\n <li>Sharply growing top-line revenue from a small base</li>\n <li>A swing to gross profit and positive gross margin</li>\n <li>High and increasing operating losses</li>\n <li>High and increasing cash used in operations</li>\n</ul>\n<p>Below are relevant financial results derived from the firm’s registration statement:</p>\n<p><img src=\"https://static.tigerbbs.com/6fb31b91e96ed681b39c952c72b32105\" tg-width=\"904\" tg-height=\"439\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/94b04bc1fd096b33535887c4c77d17a5\" tg-width=\"906\" tg-height=\"442\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/72b3c6e00fbb7d021141642eb8f69104\" tg-width=\"907\" tg-height=\"441\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/43410c6bd6487d96c4424db32f9c94e7\" tg-width=\"907\" tg-height=\"438\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/0457da194f7ee652bf4bad3deb6fbf40\" tg-width=\"908\" tg-height=\"441\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/12ac204e8226347ff04eb9ca845142aa\" tg-width=\"902\" tg-height=\"439\" referrerpolicy=\"no-referrer\"></p>\n<p>As of June 30, 2021, Procept had $159.2 million in cash and $68.3 million in total liabilities.</p>\n<p>Free cash flow during the twelve months ended June 30, 2021, was negative ($52.7 million).</p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Procept BioRobotics spikes 40% on its first day of trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nProcept BioRobotics spikes 40% on its first day of trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-09-16 00:03</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Procept BioRobotics spikes 40% on its first day of trading.</p>\n<p><img src=\"https://static.tigerbbs.com/70f6e6c88567a43f408cd96f913f6476\" tg-width=\"1404\" tg-height=\"888\" width=\"100%\" height=\"auto\"></p>\n<p>Procept BioRobotics Corp.&nbsp;is set to go public Wednesday, as the California-based surgical robotics company's upsized initial public offering priced above the expected range at $25.00 per share. The company sold 6.56 million shares in the IPO to raise $163.9 million. Procept had previously expected to offer 5.5 million shares in the IPO, which was projected to price between $22 and $24 per share. The stock is expected to begin trading Wednesday on the Nasdaq under the ticker symbol \"PRCT.\" With 41.21 million shares outstanding after the IPO, the pricing values Procept at $1.03 billion. BofA Securities and Goldman Sachs are the joint lead bookrunning managers. The company had recorded a net loss of $27.4 million on revenue of $15.7 million in the six months ended June 30, after a loss of $25.7 million on revenue of $2.4 million in the same period a year ago. The company is going public at a time that the <a href=\"https://laohu8.com/S/IPO\">Renaissance IPO ETF</a>&nbsp;has gained 7.4% over the past three months while the S&amp;P 500 has tacked on 4.6%.</p>\n<p><b>Company and Technology</b></p>\n<p>Redwood City, California-based Procept was founded to develop advanced surgical robotic devices for use in minimally invasive procedures.</p>\n<p>Management is headed by President and CEO Reza Zadno, Ph.D., who has been with the firm since February 2020 and was previously president and CEO of Avedro, a healthcare company.</p>\n<p>The company's first instrument is the AquaBeam Robotic System for use in urologic surgery with an initial focus on treating benign prostate hyperplasia.</p>\n<p>Procept has received at least $328 million in equity investment from investors including CPMG, Viking Global, Fidelity and individuals.</p>\n<p>Customer Acquisition</p>\n<p>The firm sells its product to hospitals who in turn charge various third party payors for each service rendered.</p>\n<p>The company is targeting 860 high-volume hospitals which account for 70% of all hospital-based resective procedures.</p>\n<p>Selling, G&amp;A expenses as a percentage of total revenue have dropped substantially as revenues have increased, as the figures below indicate:</p>\n<table>\n <colgroup></colgroup>\n <tbody>\n  <tr>\n   <td><p><b>Selling, G&amp;A</b></p></td>\n   <td><p><b>Expenses vs. Revenue</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Percentage</p></td>\n  </tr>\n  <tr>\n   <td><p>Six Mos. Ended June 30, 2021</p></td>\n   <td><p>144.5%</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>392.3%</p></td>\n  </tr>\n  <tr>\n   <td><p>2019</p></td>\n   <td><p>462.3%</p></td>\n  </tr>\n </tbody>\n</table>\n<p>The Selling, G&amp;A efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Selling, G&amp;A spend, rose to 0.6x in the most recent reporting period, as shown in the table below:</p>\n<table>\n <colgroup></colgroup>\n <tbody>\n  <tr>\n   <td><p><b>Selling, G&amp;A</b></p></td>\n   <td><p><b>Efficiency Rate</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Multiple</p></td>\n  </tr>\n  <tr>\n   <td><p>Six Mos. Ended June 30, 2021</p></td>\n   <td><p>0.6</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>0.1</p></td>\n  </tr>\n </tbody>\n</table>\n<p><b>Market &amp; Competition</b></p>\n<p>According to a 2018 marketresearch reportby Allied Market Research, the global market for treating benign prostatic hyperplasia was an estimated $10.7 billion in 2017 and is forecast to reach $20.1 billion by 2025.</p>\n<p>This represents a forecast CAGR of 8.1% from 2018 to 2025.</p>\n<p>The main drivers for this expected growth are an increase in disease incidence to the aging of the global population of males.</p>\n<p>Also, alpha-blocker drugs are likely to be a major competitor, as they help in relaxing the muscle of the prostate and the bladder neck, allowing urination to occur more easily.</p>\n<p>Major competitive or other industry participants include:</p>\n<ul>\n <li>Boehringer Ingelheim</li>\n <li>Allergan</li>\n <li>GlaxoSmithKline(NYSE:GSK)</li>\n <li>Merck(NYSE:MRK)</li>\n <li>Teleflex(NYSE:TFX)</li>\n <li>Boston Scientific(NYSE:BSX)</li>\n <li>Others</li>\n</ul>\n<p><b>Financial Performance</b></p>\n<p>Procept’s recent financial results can be summarized as follows:</p>\n<ul>\n <li>Sharply growing top-line revenue from a small base</li>\n <li>A swing to gross profit and positive gross margin</li>\n <li>High and increasing operating losses</li>\n <li>High and increasing cash used in operations</li>\n</ul>\n<p>Below are relevant financial results derived from the firm’s registration statement:</p>\n<p><img src=\"https://static.tigerbbs.com/6fb31b91e96ed681b39c952c72b32105\" tg-width=\"904\" tg-height=\"439\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/94b04bc1fd096b33535887c4c77d17a5\" tg-width=\"906\" tg-height=\"442\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/72b3c6e00fbb7d021141642eb8f69104\" tg-width=\"907\" tg-height=\"441\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/43410c6bd6487d96c4424db32f9c94e7\" tg-width=\"907\" tg-height=\"438\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/0457da194f7ee652bf4bad3deb6fbf40\" tg-width=\"908\" tg-height=\"441\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/12ac204e8226347ff04eb9ca845142aa\" tg-width=\"902\" tg-height=\"439\" referrerpolicy=\"no-referrer\"></p>\n<p>As of June 30, 2021, Procept had $159.2 million in cash and $68.3 million in total liabilities.</p>\n<p>Free cash flow during the twelve months ended June 30, 2021, was negative ($52.7 million).</p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PRCT":"PROCEPT BioRobotics"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2167559884","content_text":"Procept BioRobotics spikes 40% on its first day of trading.\n\nProcept BioRobotics Corp. is set to go public Wednesday, as the California-based surgical robotics company's upsized initial public offering priced above the expected range at $25.00 per share. The company sold 6.56 million shares in the IPO to raise $163.9 million. Procept had previously expected to offer 5.5 million shares in the IPO, which was projected to price between $22 and $24 per share. The stock is expected to begin trading Wednesday on the Nasdaq under the ticker symbol \"PRCT.\" With 41.21 million shares outstanding after the IPO, the pricing values Procept at $1.03 billion. BofA Securities and Goldman Sachs are the joint lead bookrunning managers. The company had recorded a net loss of $27.4 million on revenue of $15.7 million in the six months ended June 30, after a loss of $25.7 million on revenue of $2.4 million in the same period a year ago. The company is going public at a time that the Renaissance IPO ETF has gained 7.4% over the past three months while the S&P 500 has tacked on 4.6%.\nCompany and Technology\nRedwood City, California-based Procept was founded to develop advanced surgical robotic devices for use in minimally invasive procedures.\nManagement is headed by President and CEO Reza Zadno, Ph.D., who has been with the firm since February 2020 and was previously president and CEO of Avedro, a healthcare company.\nThe company's first instrument is the AquaBeam Robotic System for use in urologic surgery with an initial focus on treating benign prostate hyperplasia.\nProcept has received at least $328 million in equity investment from investors including CPMG, Viking Global, Fidelity and individuals.\nCustomer Acquisition\nThe firm sells its product to hospitals who in turn charge various third party payors for each service rendered.\nThe company is targeting 860 high-volume hospitals which account for 70% of all hospital-based resective procedures.\nSelling, G&A expenses as a percentage of total revenue have dropped substantially as revenues have increased, as the figures below indicate:\n\n\n\n\nSelling, G&A\nExpenses vs. Revenue\n\n\nPeriod\nPercentage\n\n\nSix Mos. Ended June 30, 2021\n144.5%\n\n\n2020\n392.3%\n\n\n2019\n462.3%\n\n\n\nThe Selling, G&A efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Selling, G&A spend, rose to 0.6x in the most recent reporting period, as shown in the table below:\n\n\n\n\nSelling, G&A\nEfficiency Rate\n\n\nPeriod\nMultiple\n\n\nSix Mos. Ended June 30, 2021\n0.6\n\n\n2020\n0.1\n\n\n\nMarket & Competition\nAccording to a 2018 marketresearch reportby Allied Market Research, the global market for treating benign prostatic hyperplasia was an estimated $10.7 billion in 2017 and is forecast to reach $20.1 billion by 2025.\nThis represents a forecast CAGR of 8.1% from 2018 to 2025.\nThe main drivers for this expected growth are an increase in disease incidence to the aging of the global population of males.\nAlso, alpha-blocker drugs are likely to be a major competitor, as they help in relaxing the muscle of the prostate and the bladder neck, allowing urination to occur more easily.\nMajor competitive or other industry participants include:\n\nBoehringer Ingelheim\nAllergan\nGlaxoSmithKline(NYSE:GSK)\nMerck(NYSE:MRK)\nTeleflex(NYSE:TFX)\nBoston Scientific(NYSE:BSX)\nOthers\n\nFinancial Performance\nProcept’s recent financial results can be summarized as follows:\n\nSharply growing top-line revenue from a small base\nA swing to gross profit and positive gross margin\nHigh and increasing operating losses\nHigh and increasing cash used in operations\n\nBelow are relevant financial results derived from the firm’s registration statement:\n\nAs of June 30, 2021, Procept had $159.2 million in cash and $68.3 million in total liabilities.\nFree cash flow during the twelve months ended June 30, 2021, was negative ($52.7 million).","news_type":1},"isVote":1,"tweetType":1,"viewCount":250,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":869838777,"gmtCreate":1632271331099,"gmtModify":1676530739361,"author":{"id":"3580436163482352","authorId":"3580436163482352","name":"JohnLoh00","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/869838777","repostId":"2169637141","repostType":4,"isVote":1,"tweetType":1,"viewCount":113,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":885045807,"gmtCreate":1631748395909,"gmtModify":1676530622670,"author":{"id":"3580436163482352","authorId":"3580436163482352","name":"JohnLoh00","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/885045807","repostId":"1121883775","repostType":4,"repost":{"id":"1121883775","pubTimestamp":1631719213,"share":"https://www.laohu8.com/m/news/1121883775?lang=&edition=full","pubTime":"2021-09-15 23:20","market":"us","language":"en","title":"For GameStop Stock Investors, Perception May Be Reality That’s in the Way","url":"https://stock-news.laohu8.com/highlight/detail?id=1121883775","media":"InvestorPlace","summary":"Now a leaner company, GME stock may be whatever investors want it to be","content":"<p>There are few things more powerful than your own beliefs. This is playing out in a big way with the meme stock trade, particularly with the original,<b>GameStop</b>&nbsp;(NYSE:<b><u>GME</u></b>). And eight months after trading for over $500 per share, GME stock remains one of the most intriguing.</p>\n<p>Did I just say put “GME stock” and “intriguing” in the same sentence? I did, but probably not for the reason you may think. The company has made a smart pivot to e-commerce. And retail investors have helped fund this transition as evidenced by the $1.1 billion at-the-market offering the company conducted in June.</p>\n<p>As a result of that transition, GameStop is emerging as a leaner company. On the second-quarter&nbsp;earnings call, CEO Matt Furlong remarked that GameStop’s year-over-year debt level was down $424.7 million. He also remarked that the company’s only long-term debt is a $47.5 million low-interest unsecured term loan.</p>\n<p><b>Difficult ComparisonsChallenge GME Stock</b></p>\n<p>However, while revenue is trending in the right direction, the comparisons become difficult. GameStop’s fiscal year runs from February through January. And for the first two quarters of this year, GameStop delivered revenue of $1.28 billion and $1.18 billion. That is higher than in FY2020 when the company reported revenue of $1.02 billion and $942 million in the respective quarters.</p>\n<p>But that may not be a fair comparison. So I looked back to FY2019. And the revenue for the first two quarters of that year came in at $1.55 billion and $1.29 billion, respectively. That’s a 13% decline.</p>\n<p>I know that GME bulls will say that I’m not comparing apples to apples. In 2019, the company was relying on revenue from its brick-and-mortar business. Now the company is focused on e-commerce. And investors would be quick to point out that hardware sales are being affected by the global chip shortage. Except they’re not. In fact, hardware sales were up on a year-over-year basis.</p>\n<p>The more alarming trend is software sales, which continue to be in free fall. And with more and more gamers opting for digital downloads, it’s unlikely that the company will be able to reverse this trend.</p>\n<p>Plus the company is not completely reliant on e-commerce at this time. On the earnings call, Furlong noted that the company reported a 9% reduction in its “global store fleet.” This is a good move, but the transition will still take time.</p>\n<p><b>What Comes Next?</b></p>\n<p>This is where things become more problematic. Specifically because GameStop is not offering investors any forward guidance. However, the company did reiterate that they “believe total net sales is the most appropriate metric to evaluate performance at this time.”</p>\n<p>This is why&nbsp;I believe that the perception of GameStop may be all that matters.</p>\n<p>GME stock bulls will say the analyst community unfairly is stuck in the past and fails to see the e-commerce opportunity that exists. However, GME skeptics will point out that GameStop is attempting to compete in a hyper-competitive market.</p>\n<p><b>GME Stock is Developing a Pattern</b></p>\n<p>They say when something happens three times,it becomes a pattern. So I find it intriguing that for the third-straight earnings report, GME stock has gapped down after earnings. When this happened in March, the stock recovered its former share price and, in fact, closed as high as $300 before the company’s June earnings.</p>\n<p>However, since then the stock has been on a steady downtrend. And that’s why I’m still of the mindset that GameStop has a heavy lift.</p>\n<p>I think&nbsp;<i>InvestorPlace</i>&nbsp;contributor Thomas Niel summarized my feelings best when discussing therisk/reward scenariofor GME stock. Simply put, it’s more likely that over time (those are critical words), the likelihood for the stock to take a large move down appears to be greater than the possibility that the stock will soar higher.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>For GameStop Stock Investors, Perception May Be Reality That’s in the Way</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFor GameStop Stock Investors, Perception May Be Reality That’s in the Way\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-15 23:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/09/gme-stock-remains-question-perception-versus-reality/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>There are few things more powerful than your own beliefs. This is playing out in a big way with the meme stock trade, particularly with the original,GameStop (NYSE:GME). And eight months after trading...</p>\n\n<a href=\"https://investorplace.com/2021/09/gme-stock-remains-question-perception-versus-reality/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GME":"游戏驿站"},"source_url":"https://investorplace.com/2021/09/gme-stock-remains-question-perception-versus-reality/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1121883775","content_text":"There are few things more powerful than your own beliefs. This is playing out in a big way with the meme stock trade, particularly with the original,GameStop (NYSE:GME). And eight months after trading for over $500 per share, GME stock remains one of the most intriguing.\nDid I just say put “GME stock” and “intriguing” in the same sentence? I did, but probably not for the reason you may think. The company has made a smart pivot to e-commerce. And retail investors have helped fund this transition as evidenced by the $1.1 billion at-the-market offering the company conducted in June.\nAs a result of that transition, GameStop is emerging as a leaner company. On the second-quarter earnings call, CEO Matt Furlong remarked that GameStop’s year-over-year debt level was down $424.7 million. He also remarked that the company’s only long-term debt is a $47.5 million low-interest unsecured term loan.\nDifficult ComparisonsChallenge GME Stock\nHowever, while revenue is trending in the right direction, the comparisons become difficult. GameStop’s fiscal year runs from February through January. And for the first two quarters of this year, GameStop delivered revenue of $1.28 billion and $1.18 billion. That is higher than in FY2020 when the company reported revenue of $1.02 billion and $942 million in the respective quarters.\nBut that may not be a fair comparison. So I looked back to FY2019. And the revenue for the first two quarters of that year came in at $1.55 billion and $1.29 billion, respectively. That’s a 13% decline.\nI know that GME bulls will say that I’m not comparing apples to apples. In 2019, the company was relying on revenue from its brick-and-mortar business. Now the company is focused on e-commerce. And investors would be quick to point out that hardware sales are being affected by the global chip shortage. Except they’re not. In fact, hardware sales were up on a year-over-year basis.\nThe more alarming trend is software sales, which continue to be in free fall. And with more and more gamers opting for digital downloads, it’s unlikely that the company will be able to reverse this trend.\nPlus the company is not completely reliant on e-commerce at this time. On the earnings call, Furlong noted that the company reported a 9% reduction in its “global store fleet.” This is a good move, but the transition will still take time.\nWhat Comes Next?\nThis is where things become more problematic. Specifically because GameStop is not offering investors any forward guidance. However, the company did reiterate that they “believe total net sales is the most appropriate metric to evaluate performance at this time.”\nThis is why I believe that the perception of GameStop may be all that matters.\nGME stock bulls will say the analyst community unfairly is stuck in the past and fails to see the e-commerce opportunity that exists. However, GME skeptics will point out that GameStop is attempting to compete in a hyper-competitive market.\nGME Stock is Developing a Pattern\nThey say when something happens three times,it becomes a pattern. So I find it intriguing that for the third-straight earnings report, GME stock has gapped down after earnings. When this happened in March, the stock recovered its former share price and, in fact, closed as high as $300 before the company’s June earnings.\nHowever, since then the stock has been on a steady downtrend. And that’s why I’m still of the mindset that GameStop has a heavy lift.\nI think InvestorPlace contributor Thomas Niel summarized my feelings best when discussing therisk/reward scenariofor GME stock. Simply put, it’s more likely that over time (those are critical words), the likelihood for the stock to take a large move down appears to be greater than the possibility that the stock will soar higher.","news_type":1},"isVote":1,"tweetType":1,"viewCount":98,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":882896308,"gmtCreate":1631671667604,"gmtModify":1676530605216,"author":{"id":"3580436163482352","authorId":"3580436163482352","name":"JohnLoh00","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/882896308","repostId":"1194314814","repostType":4,"repost":{"id":"1194314814","pubTimestamp":1631669942,"share":"https://www.laohu8.com/m/news/1194314814?lang=&edition=full","pubTime":"2021-09-15 09:39","market":"us","language":"en","title":"SPRT Stock Plunges 30% Ahead of Greenidge Generation’s (GREE) Debut","url":"https://stock-news.laohu8.com/highlight/detail?id=1194314814","media":"investorplace","summary":"Today marks the final catalyst that we predicted for shareholders of SPRT as Support.com(NASDAQ:SPRT","content":"<p>Today marks the&nbsp;final catalyst&nbsp;that we predicted for shareholders of SPRT as&nbsp;<b>Support.com</b>(NASDAQ:<b><u>SPRT</u></b>) and&nbsp;<b>Greenidge Generation Holdings</b>&nbsp;complete&nbsp;their long-awaited merger. As of tomorrow, Greenidge Class A common stock shares will begin trading on the&nbsp;<b>Nasdaq</b>&nbsp;under the ticker GREE. This morning, though, saw shares of SPRT stock continue the trend of plunging further, despite the merger’s continuous development.</p>\n<p>As we’ve noted previously, SPRT stock has continued to decline over the past week, despite a spike during the week before. Investors chased up shares earlier in September upon news that shareholders would soon vote to approve the merger. The actual vote, though, did not have the same affect, as shares began to decline. Since then, this trend hasn’t stopped.</p>\n<p>As of this writing, shares of SPRT stock are down 30.8% for the day. After briefly surging late in the day on Sept. 9, they have only kept declining. Yesterday saw the stock fall by 9%.</p>\n<p>What It Means</p>\n<p>The deal received overwhelming support from shareholders when it came time to vote, but in the days since, some analysts have expressed concern for the company’s long-term future.</p>\n<p>Some concerns are certainly justified, although part of SPRT stock’s poor performance of late can be attributed to pure uncertainty. The deal is a bit unorthodox given the two companies it involves and how different their dealings are. Nonetheless, this area which has some concerned can also prove beneficial to Support.com and likewise, its shareholders.</p>\n<p>It should be noted that a company like Suport.com saw merging with a company like Greenidge as its best chance at staying relevant in an ever-changing market. The latter is poised to become the first publicly traded<b>Bitcoin</b>(CCC:<b><u>BTC-USD</u></b>) mining company with its own power plant, an area that could allow them to grow considerably. The move has beencalleda Hail Mary pass for Support.com but if that’s true, it’s certainly a well-calculated pass that makes sense at this point in the game.</p>\n<p>Let’s also not forget that while this merger dragged out, Support.com was able to garner meme stock status, a rare feat for a company with a business model as boring as providing digital human resource tools. Say what you will about Greenidge, but merging with it makes Support.com unquestionably more interesting.</p>\n<p>What’s Next for These Companies?</p>\n<p>Support.com stock has seen plenty of volatility and it may not be over yet, but that doesn’t mean that the company won’t have plenty of opportunity to grow once GREE begins trading and markets can move forward. Tomorrow will hopefully mean the end of this uncertainty, allowing us to finally assess how SPRT stock will perform in a post-merger world.</p>\n<p>The stock is drawing a lot of criticism right now, but we shouldn’t be so quick to write it off until we see what GREE will do. Support.com’s new partner has plenty of potential.</p>\n<p>As<i>InvestorPlace</i>contributor Tom Kerr recently&nbsp;assessed“One thing can be said for certain: now the upside for SPRT stock depends a heck of a lot more on the price of Bitcoin (CCC:<b><u>BTC-USD</u></b>).”</p>\n<p>With that in mind, we should continue to watch and wait.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SPRT Stock Plunges 30% Ahead of Greenidge Generation’s (GREE) Debut</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSPRT Stock Plunges 30% Ahead of Greenidge Generation’s (GREE) Debut\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-15 09:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/09/sprt-stock-plunges-30-ahead-of-greenidge-generations-gree-debut/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Today marks the final catalyst that we predicted for shareholders of SPRT as Support.com(NASDAQ:SPRT) and Greenidge Generation Holdings complete their long-awaited merger. As of tomorrow, Greenidge ...</p>\n\n<a href=\"https://investorplace.com/2021/09/sprt-stock-plunges-30-ahead-of-greenidge-generations-gree-debut/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://investorplace.com/2021/09/sprt-stock-plunges-30-ahead-of-greenidge-generations-gree-debut/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1194314814","content_text":"Today marks the final catalyst that we predicted for shareholders of SPRT as Support.com(NASDAQ:SPRT) and Greenidge Generation Holdings complete their long-awaited merger. As of tomorrow, Greenidge Class A common stock shares will begin trading on the Nasdaq under the ticker GREE. This morning, though, saw shares of SPRT stock continue the trend of plunging further, despite the merger’s continuous development.\nAs we’ve noted previously, SPRT stock has continued to decline over the past week, despite a spike during the week before. Investors chased up shares earlier in September upon news that shareholders would soon vote to approve the merger. The actual vote, though, did not have the same affect, as shares began to decline. Since then, this trend hasn’t stopped.\nAs of this writing, shares of SPRT stock are down 30.8% for the day. After briefly surging late in the day on Sept. 9, they have only kept declining. Yesterday saw the stock fall by 9%.\nWhat It Means\nThe deal received overwhelming support from shareholders when it came time to vote, but in the days since, some analysts have expressed concern for the company’s long-term future.\nSome concerns are certainly justified, although part of SPRT stock’s poor performance of late can be attributed to pure uncertainty. The deal is a bit unorthodox given the two companies it involves and how different their dealings are. Nonetheless, this area which has some concerned can also prove beneficial to Support.com and likewise, its shareholders.\nIt should be noted that a company like Suport.com saw merging with a company like Greenidge as its best chance at staying relevant in an ever-changing market. The latter is poised to become the first publicly tradedBitcoin(CCC:BTC-USD) mining company with its own power plant, an area that could allow them to grow considerably. The move has beencalleda Hail Mary pass for Support.com but if that’s true, it’s certainly a well-calculated pass that makes sense at this point in the game.\nLet’s also not forget that while this merger dragged out, Support.com was able to garner meme stock status, a rare feat for a company with a business model as boring as providing digital human resource tools. Say what you will about Greenidge, but merging with it makes Support.com unquestionably more interesting.\nWhat’s Next for These Companies?\nSupport.com stock has seen plenty of volatility and it may not be over yet, but that doesn’t mean that the company won’t have plenty of opportunity to grow once GREE begins trading and markets can move forward. Tomorrow will hopefully mean the end of this uncertainty, allowing us to finally assess how SPRT stock will perform in a post-merger world.\nThe stock is drawing a lot of criticism right now, but we shouldn’t be so quick to write it off until we see what GREE will do. Support.com’s new partner has plenty of potential.\nAsInvestorPlacecontributor Tom Kerr recently assessed“One thing can be said for certain: now the upside for SPRT stock depends a heck of a lot more on the price of Bitcoin (CCC:BTC-USD).”\nWith that in mind, we should continue to watch and wait.","news_type":1},"isVote":1,"tweetType":1,"viewCount":35,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":885042243,"gmtCreate":1631748359982,"gmtModify":1676530622638,"author":{"id":"3580436163482352","authorId":"3580436163482352","name":"JohnLoh00","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/885042243","repostId":"2167559884","repostType":4,"repost":{"id":"2167559884","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1631721822,"share":"https://www.laohu8.com/m/news/2167559884?lang=&edition=full","pubTime":"2021-09-16 00:03","market":"us","language":"en","title":"Procept BioRobotics spikes 40% on its first day of trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2167559884","media":"Dow Jones","summary":"Procept BioRobotics spikes 40% on its first day of trading.\n\nProcept BioRobotics Corp. is set to go ","content":"<p>Procept BioRobotics spikes 40% on its first day of trading.</p>\n<p><img src=\"https://static.tigerbbs.com/70f6e6c88567a43f408cd96f913f6476\" tg-width=\"1404\" tg-height=\"888\" width=\"100%\" height=\"auto\"></p>\n<p>Procept BioRobotics Corp.&nbsp;is set to go public Wednesday, as the California-based surgical robotics company's upsized initial public offering priced above the expected range at $25.00 per share. The company sold 6.56 million shares in the IPO to raise $163.9 million. Procept had previously expected to offer 5.5 million shares in the IPO, which was projected to price between $22 and $24 per share. The stock is expected to begin trading Wednesday on the Nasdaq under the ticker symbol \"PRCT.\" With 41.21 million shares outstanding after the IPO, the pricing values Procept at $1.03 billion. BofA Securities and Goldman Sachs are the joint lead bookrunning managers. The company had recorded a net loss of $27.4 million on revenue of $15.7 million in the six months ended June 30, after a loss of $25.7 million on revenue of $2.4 million in the same period a year ago. The company is going public at a time that the <a href=\"https://laohu8.com/S/IPO\">Renaissance IPO ETF</a>&nbsp;has gained 7.4% over the past three months while the S&amp;P 500 has tacked on 4.6%.</p>\n<p><b>Company and Technology</b></p>\n<p>Redwood City, California-based Procept was founded to develop advanced surgical robotic devices for use in minimally invasive procedures.</p>\n<p>Management is headed by President and CEO Reza Zadno, Ph.D., who has been with the firm since February 2020 and was previously president and CEO of Avedro, a healthcare company.</p>\n<p>The company's first instrument is the AquaBeam Robotic System for use in urologic surgery with an initial focus on treating benign prostate hyperplasia.</p>\n<p>Procept has received at least $328 million in equity investment from investors including CPMG, Viking Global, Fidelity and individuals.</p>\n<p>Customer Acquisition</p>\n<p>The firm sells its product to hospitals who in turn charge various third party payors for each service rendered.</p>\n<p>The company is targeting 860 high-volume hospitals which account for 70% of all hospital-based resective procedures.</p>\n<p>Selling, G&amp;A expenses as a percentage of total revenue have dropped substantially as revenues have increased, as the figures below indicate:</p>\n<table>\n <colgroup></colgroup>\n <tbody>\n  <tr>\n   <td><p><b>Selling, G&amp;A</b></p></td>\n   <td><p><b>Expenses vs. Revenue</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Percentage</p></td>\n  </tr>\n  <tr>\n   <td><p>Six Mos. Ended June 30, 2021</p></td>\n   <td><p>144.5%</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>392.3%</p></td>\n  </tr>\n  <tr>\n   <td><p>2019</p></td>\n   <td><p>462.3%</p></td>\n  </tr>\n </tbody>\n</table>\n<p>The Selling, G&amp;A efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Selling, G&amp;A spend, rose to 0.6x in the most recent reporting period, as shown in the table below:</p>\n<table>\n <colgroup></colgroup>\n <tbody>\n  <tr>\n   <td><p><b>Selling, G&amp;A</b></p></td>\n   <td><p><b>Efficiency Rate</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Multiple</p></td>\n  </tr>\n  <tr>\n   <td><p>Six Mos. Ended June 30, 2021</p></td>\n   <td><p>0.6</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>0.1</p></td>\n  </tr>\n </tbody>\n</table>\n<p><b>Market &amp; Competition</b></p>\n<p>According to a 2018 marketresearch reportby Allied Market Research, the global market for treating benign prostatic hyperplasia was an estimated $10.7 billion in 2017 and is forecast to reach $20.1 billion by 2025.</p>\n<p>This represents a forecast CAGR of 8.1% from 2018 to 2025.</p>\n<p>The main drivers for this expected growth are an increase in disease incidence to the aging of the global population of males.</p>\n<p>Also, alpha-blocker drugs are likely to be a major competitor, as they help in relaxing the muscle of the prostate and the bladder neck, allowing urination to occur more easily.</p>\n<p>Major competitive or other industry participants include:</p>\n<ul>\n <li>Boehringer Ingelheim</li>\n <li>Allergan</li>\n <li>GlaxoSmithKline(NYSE:GSK)</li>\n <li>Merck(NYSE:MRK)</li>\n <li>Teleflex(NYSE:TFX)</li>\n <li>Boston Scientific(NYSE:BSX)</li>\n <li>Others</li>\n</ul>\n<p><b>Financial Performance</b></p>\n<p>Procept’s recent financial results can be summarized as follows:</p>\n<ul>\n <li>Sharply growing top-line revenue from a small base</li>\n <li>A swing to gross profit and positive gross margin</li>\n <li>High and increasing operating losses</li>\n <li>High and increasing cash used in operations</li>\n</ul>\n<p>Below are relevant financial results derived from the firm’s registration statement:</p>\n<p><img src=\"https://static.tigerbbs.com/6fb31b91e96ed681b39c952c72b32105\" tg-width=\"904\" tg-height=\"439\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/94b04bc1fd096b33535887c4c77d17a5\" tg-width=\"906\" tg-height=\"442\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/72b3c6e00fbb7d021141642eb8f69104\" tg-width=\"907\" tg-height=\"441\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/43410c6bd6487d96c4424db32f9c94e7\" tg-width=\"907\" tg-height=\"438\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/0457da194f7ee652bf4bad3deb6fbf40\" tg-width=\"908\" tg-height=\"441\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/12ac204e8226347ff04eb9ca845142aa\" tg-width=\"902\" tg-height=\"439\" referrerpolicy=\"no-referrer\"></p>\n<p>As of June 30, 2021, Procept had $159.2 million in cash and $68.3 million in total liabilities.</p>\n<p>Free cash flow during the twelve months ended June 30, 2021, was negative ($52.7 million).</p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Procept BioRobotics spikes 40% on its first day of trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nProcept BioRobotics spikes 40% on its first day of trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-09-16 00:03</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Procept BioRobotics spikes 40% on its first day of trading.</p>\n<p><img src=\"https://static.tigerbbs.com/70f6e6c88567a43f408cd96f913f6476\" tg-width=\"1404\" tg-height=\"888\" width=\"100%\" height=\"auto\"></p>\n<p>Procept BioRobotics Corp.&nbsp;is set to go public Wednesday, as the California-based surgical robotics company's upsized initial public offering priced above the expected range at $25.00 per share. The company sold 6.56 million shares in the IPO to raise $163.9 million. Procept had previously expected to offer 5.5 million shares in the IPO, which was projected to price between $22 and $24 per share. The stock is expected to begin trading Wednesday on the Nasdaq under the ticker symbol \"PRCT.\" With 41.21 million shares outstanding after the IPO, the pricing values Procept at $1.03 billion. BofA Securities and Goldman Sachs are the joint lead bookrunning managers. The company had recorded a net loss of $27.4 million on revenue of $15.7 million in the six months ended June 30, after a loss of $25.7 million on revenue of $2.4 million in the same period a year ago. The company is going public at a time that the <a href=\"https://laohu8.com/S/IPO\">Renaissance IPO ETF</a>&nbsp;has gained 7.4% over the past three months while the S&amp;P 500 has tacked on 4.6%.</p>\n<p><b>Company and Technology</b></p>\n<p>Redwood City, California-based Procept was founded to develop advanced surgical robotic devices for use in minimally invasive procedures.</p>\n<p>Management is headed by President and CEO Reza Zadno, Ph.D., who has been with the firm since February 2020 and was previously president and CEO of Avedro, a healthcare company.</p>\n<p>The company's first instrument is the AquaBeam Robotic System for use in urologic surgery with an initial focus on treating benign prostate hyperplasia.</p>\n<p>Procept has received at least $328 million in equity investment from investors including CPMG, Viking Global, Fidelity and individuals.</p>\n<p>Customer Acquisition</p>\n<p>The firm sells its product to hospitals who in turn charge various third party payors for each service rendered.</p>\n<p>The company is targeting 860 high-volume hospitals which account for 70% of all hospital-based resective procedures.</p>\n<p>Selling, G&amp;A expenses as a percentage of total revenue have dropped substantially as revenues have increased, as the figures below indicate:</p>\n<table>\n <colgroup></colgroup>\n <tbody>\n  <tr>\n   <td><p><b>Selling, G&amp;A</b></p></td>\n   <td><p><b>Expenses vs. Revenue</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Percentage</p></td>\n  </tr>\n  <tr>\n   <td><p>Six Mos. Ended June 30, 2021</p></td>\n   <td><p>144.5%</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>392.3%</p></td>\n  </tr>\n  <tr>\n   <td><p>2019</p></td>\n   <td><p>462.3%</p></td>\n  </tr>\n </tbody>\n</table>\n<p>The Selling, G&amp;A efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Selling, G&amp;A spend, rose to 0.6x in the most recent reporting period, as shown in the table below:</p>\n<table>\n <colgroup></colgroup>\n <tbody>\n  <tr>\n   <td><p><b>Selling, G&amp;A</b></p></td>\n   <td><p><b>Efficiency Rate</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Multiple</p></td>\n  </tr>\n  <tr>\n   <td><p>Six Mos. Ended June 30, 2021</p></td>\n   <td><p>0.6</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>0.1</p></td>\n  </tr>\n </tbody>\n</table>\n<p><b>Market &amp; Competition</b></p>\n<p>According to a 2018 marketresearch reportby Allied Market Research, the global market for treating benign prostatic hyperplasia was an estimated $10.7 billion in 2017 and is forecast to reach $20.1 billion by 2025.</p>\n<p>This represents a forecast CAGR of 8.1% from 2018 to 2025.</p>\n<p>The main drivers for this expected growth are an increase in disease incidence to the aging of the global population of males.</p>\n<p>Also, alpha-blocker drugs are likely to be a major competitor, as they help in relaxing the muscle of the prostate and the bladder neck, allowing urination to occur more easily.</p>\n<p>Major competitive or other industry participants include:</p>\n<ul>\n <li>Boehringer Ingelheim</li>\n <li>Allergan</li>\n <li>GlaxoSmithKline(NYSE:GSK)</li>\n <li>Merck(NYSE:MRK)</li>\n <li>Teleflex(NYSE:TFX)</li>\n <li>Boston Scientific(NYSE:BSX)</li>\n <li>Others</li>\n</ul>\n<p><b>Financial Performance</b></p>\n<p>Procept’s recent financial results can be summarized as follows:</p>\n<ul>\n <li>Sharply growing top-line revenue from a small base</li>\n <li>A swing to gross profit and positive gross margin</li>\n <li>High and increasing operating losses</li>\n <li>High and increasing cash used in operations</li>\n</ul>\n<p>Below are relevant financial results derived from the firm’s registration statement:</p>\n<p><img src=\"https://static.tigerbbs.com/6fb31b91e96ed681b39c952c72b32105\" tg-width=\"904\" tg-height=\"439\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/94b04bc1fd096b33535887c4c77d17a5\" tg-width=\"906\" tg-height=\"442\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/72b3c6e00fbb7d021141642eb8f69104\" tg-width=\"907\" tg-height=\"441\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/43410c6bd6487d96c4424db32f9c94e7\" tg-width=\"907\" tg-height=\"438\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/0457da194f7ee652bf4bad3deb6fbf40\" tg-width=\"908\" tg-height=\"441\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/12ac204e8226347ff04eb9ca845142aa\" tg-width=\"902\" tg-height=\"439\" referrerpolicy=\"no-referrer\"></p>\n<p>As of June 30, 2021, Procept had $159.2 million in cash and $68.3 million in total liabilities.</p>\n<p>Free cash flow during the twelve months ended June 30, 2021, was negative ($52.7 million).</p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PRCT":"PROCEPT BioRobotics"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2167559884","content_text":"Procept BioRobotics spikes 40% on its first day of trading.\n\nProcept BioRobotics Corp. is set to go public Wednesday, as the California-based surgical robotics company's upsized initial public offering priced above the expected range at $25.00 per share. The company sold 6.56 million shares in the IPO to raise $163.9 million. Procept had previously expected to offer 5.5 million shares in the IPO, which was projected to price between $22 and $24 per share. The stock is expected to begin trading Wednesday on the Nasdaq under the ticker symbol \"PRCT.\" With 41.21 million shares outstanding after the IPO, the pricing values Procept at $1.03 billion. BofA Securities and Goldman Sachs are the joint lead bookrunning managers. The company had recorded a net loss of $27.4 million on revenue of $15.7 million in the six months ended June 30, after a loss of $25.7 million on revenue of $2.4 million in the same period a year ago. The company is going public at a time that the Renaissance IPO ETF has gained 7.4% over the past three months while the S&P 500 has tacked on 4.6%.\nCompany and Technology\nRedwood City, California-based Procept was founded to develop advanced surgical robotic devices for use in minimally invasive procedures.\nManagement is headed by President and CEO Reza Zadno, Ph.D., who has been with the firm since February 2020 and was previously president and CEO of Avedro, a healthcare company.\nThe company's first instrument is the AquaBeam Robotic System for use in urologic surgery with an initial focus on treating benign prostate hyperplasia.\nProcept has received at least $328 million in equity investment from investors including CPMG, Viking Global, Fidelity and individuals.\nCustomer Acquisition\nThe firm sells its product to hospitals who in turn charge various third party payors for each service rendered.\nThe company is targeting 860 high-volume hospitals which account for 70% of all hospital-based resective procedures.\nSelling, G&A expenses as a percentage of total revenue have dropped substantially as revenues have increased, as the figures below indicate:\n\n\n\n\nSelling, G&A\nExpenses vs. Revenue\n\n\nPeriod\nPercentage\n\n\nSix Mos. Ended June 30, 2021\n144.5%\n\n\n2020\n392.3%\n\n\n2019\n462.3%\n\n\n\nThe Selling, G&A efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Selling, G&A spend, rose to 0.6x in the most recent reporting period, as shown in the table below:\n\n\n\n\nSelling, G&A\nEfficiency Rate\n\n\nPeriod\nMultiple\n\n\nSix Mos. Ended June 30, 2021\n0.6\n\n\n2020\n0.1\n\n\n\nMarket & Competition\nAccording to a 2018 marketresearch reportby Allied Market Research, the global market for treating benign prostatic hyperplasia was an estimated $10.7 billion in 2017 and is forecast to reach $20.1 billion by 2025.\nThis represents a forecast CAGR of 8.1% from 2018 to 2025.\nThe main drivers for this expected growth are an increase in disease incidence to the aging of the global population of males.\nAlso, alpha-blocker drugs are likely to be a major competitor, as they help in relaxing the muscle of the prostate and the bladder neck, allowing urination to occur more easily.\nMajor competitive or other industry participants include:\n\nBoehringer Ingelheim\nAllergan\nGlaxoSmithKline(NYSE:GSK)\nMerck(NYSE:MRK)\nTeleflex(NYSE:TFX)\nBoston Scientific(NYSE:BSX)\nOthers\n\nFinancial Performance\nProcept’s recent financial results can be summarized as follows:\n\nSharply growing top-line revenue from a small base\nA swing to gross profit and positive gross margin\nHigh and increasing operating losses\nHigh and increasing cash used in operations\n\nBelow are relevant financial results derived from the firm’s registration statement:\n\nAs of June 30, 2021, Procept had $159.2 million in cash and $68.3 million in total liabilities.\nFree cash flow during the twelve months ended June 30, 2021, was negative ($52.7 million).","news_type":1},"isVote":1,"tweetType":1,"viewCount":139,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}